

Review

Not peer-reviewed version

Lipid Nanoparticles as Active Biointerfaces: From Membrane Interaction to Systemic Dysregulation

[Falko Seger](#), L. Maria Gutschli, [Stephanie Seneff](#)*

Posted Date: 7 November 2025

doi: 10.20944/preprints202511.0517.v1

Keywords: Lipid nanoparticles; mRNA therapeutics; Oxidative stress; Phosphatidylinositol cycle; Membrane disruption; Signaling cascades; MAPK/ERK pathway; PPAR γ ; AMPK; mTOR



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Review

Lipid Nanoparticles as Active Biointerfaces: From Membrane Interaction to Systemic Dysregulation

Falko Seger¹, L. Maria Gutschli² and Stephanie Seneff^{3,*}

¹ Independent Researcher, Germany

² Independent Researcher, Canada

³ Computer Science and Artificial Intelligence Laboratory, MIT, Cambridge, MA 96722, USA

* Correspondence: seneff@csail.mit.edu

Highlights

1. Lipid nanoparticles act as biologically active structures that can initiate immune and cellular stress responses even in the absence of messenger RNA cargo.
2. Exposure to lipid nanoparticles leads to membrane disturbance, oxidative stress, and altered signal transduction involving key cellular communication pathways.
3. Cellular and molecular data indicate that lipid nanoparticles interfere with normal lipid metabolism, detoxification, and energy balance.
4. The phosphatidylinositol cycle plays a central role in lipid nanoparticle-driven membrane dysfunction (L-DMD), linking changes at the cell surface to widespread disturbances inside the cell.
5. Persistent activation of stress pathways and disruption of membrane organization suggest that lipid nanoparticles may induce long-term alterations in cellular homeostasis.

Abstract

Lipid nanoparticles (LNPs) are a critical structural element of modern mRNA therapeutics, including COVID-19 mRNA vaccines. Each formulation is a multicomponent system in which the LNP serves not as a passive carrier but as an active, biointeractive entity whose ionizable lipids engage directly with cellular membranes. Current evidence from cellular, transcriptomic, and proteomic analyses indicates that LNPs, with or without active mRNA cargo, alter transcriptomic programs and protein expression. This suggests that, even during uptake and interaction with the membrane (transfection), the membrane serves as an initial site for inflammatory, detoxifying, and stress responses. Simultaneously, pathways involved in fat metabolism and detoxification are affected, such as the peroxisome proliferator-activated receptor γ (PPAR γ) and cytochrome P450 (CYP) enzyme systems. We believe that the phosphatidylinositol (PI) cycle is the initial point for these disorders. This cycle regulates both organelle trafficking and membrane restructuring following endocytic processes, including macropinocytosis. When this cycle is disrupted, membrane restructuring and organelle dysfunction occur, triggering downstream signaling cascades such as nuclear factor kappa-B (NF- κ B), mitogen-activated protein kinases (MAPKs), Janus kinase-signal transducer (JAK-STAT) pathways, and mechanistic target of rapamycin (mTOR) complexes. Transfection with LNPs may induce a systemic condition we call lipid-nanoparticle-driven membrane dysfunction (L-DMD), where transfection results in broader dysregulation of cellular communication, stress response, and energy balance. This hypothesis-driven review offers a mechanistic foundation for understanding the diffuse, often enduring, biological effects observed after exposure to messenger RNA LNP formulations. It highlights a needed perspective at the intracellular level and within systems biology.

Keywords: lipid nanoparticles; mRNA therapeutics; oxidative stress; phosphatidylinositol cycle; membrane disruption; signaling cascades; MAPK/ERK pathway; PPAR γ ; AMPK; mTOR

1. Introduction

Lipid nanoparticles (LNPs) used in mRNA vaccine technology are engineered to resemble low-density lipoprotein (LDL) particles in many ways, by mimicking their size and structure, so as to exploit their natural mechanisms to gain cell entry through endocytosis. The nanoparticles are crucial for the successful delivery of the vaccine contents. They protect the encapsulated mRNA from ribonucleases and facilitate delivery of intact mRNA to the target site, by improving cellular penetration and facilitating endosomal escape [1].

Four distinct types of lipids are included in engineered lipid nanoparticles: cationic or ionizable lipids, cholesterol, phospholipids, and PEGylated lipids. The cationic ionizable lipids aid in endosomal escape, cholesterol stabilizes the membrane and aids in fusion, and phospholipids stabilize the lipid bilayer [2]. PEGylation, through the addition of polyethylene glycol, masks the lipid particle's cationic surface charge and provides a hydrophilic stealth coating. PEGylated lipids interact with the negatively charged endosomal phospholipids through the formation of cone-shaped ion pairs [3]. PEG coatings shield the surface from aggregation, opsonization, and phagocytosis [4].

There are several ways in which the LNPs can activate the innate immune system. Severe, even life-threatening, adverse reactions can occur due to IgE-mediated allergic reactions that are triggered through induced IgE antibodies to PEGylated particles [5–7]. Complement-associated pseudo-allergy (CARPA) due to anti-PEG IgM antibodies can induce mast cell activation and histamine release, resulting in allergic reactions, sometimes severe [8]. At the cellular level, nanoparticles can bind toll-like receptor 4 (TLR4) and activate both MyD88- and TRIF-dependent pathways [9]. It has been shown that, in THP-1 cells, both Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF- κ B) and interferon regulatory factors (IRFs) are activated [9,10]. The exact internalization mechanisms are not yet known, but it is assumed that disulfide exchange reactions between disulfide groups of oligonucleotides and membrane proteins facilitate internalization [11]. Gutschli and Seger have provided a narrative review suggesting that various receptors, such as LDL-R, mediate the binding and internalization of LNPs, according to current knowledge [12]. Furthermore, direct macropinocytosis-like uptake has also been demonstrated [13,14].

Intracellularly, the lipid nanoparticles provoke an immune response that induces the release of reactive oxygen species (ROS) [10]. This is especially concerning, given that the mRNA particles have been designed to resist degradation, leaving them vulnerable to oxidation damage for a long time [15]. There is extensive research literature on DNA damage caused by ROS, but it is generally assumed that RNA, although also susceptible and arguably even more vulnerable to many of the same chemical modifications, is generally less significant, because it typically persists for only a few hours. [16]. Cytoplasmic RNA is especially susceptible in contrast to nuclear DNA, because of the reductive environment of the nucleoplasm [17]. Due to the modifications to the mRNA done to protect it from degradation (e.g., methylpseudouridine substitution [18]), it has been shown that the mRNA delivered by the mRNA vaccines can still be present in lymph node germinal centers up to 8 weeks post-vaccination [19]. Corona formation when the particles engage with serum proteins can influence the nanoparticle's stability, cellular uptake, and biodistribution, affecting their efficacy and potentially causing an increase in adverse effects [20].

An essential consideration in understanding the biodistribution of these particles is the route of administration. A comparison between the SARS-CoV-2 mRNA vaccines and the approved siRNA-LNP drug Onpattro, used to treat hereditary transthyretin-mediated amyloidosis (hATTR), was published in 2021 [21]. Following a single intravenous infusion of siRNA-LNP, 90% of the tracked radioactivity showed up in the liver after just four hours [21], whereas, after a single intramuscular dose of the mRNA-LNP, radioactivity was concentrated at the injection site for the entire 48 hour measurement period, and did not appear in the liver until after 8-48 hours had elapsed.

The ionizable lipids in LNPs trigger a localized inflammatory response, which attracts immune cells such as neutrophils, monocytes, and dendritic cells to the injection site. These cells then internalize (most likely via transfection) the LNPs, and respond by producing inflammatory cytokines, further promoting an immune response. Following activation, dendritic cells migrate to the draining lymph nodes, where they present the antigen to resident T cells [22,23]. In experiments with both mice and primates, a study using PET-CT imaging to visualize the biodistribution of intramuscular delivery of a lipid nanoparticle designed to mimic the Moderna mRNA vaccine, showed that there was rapid trafficking to the draining lymph nodes, presumably via uptake of the cargo into immune dendritic cells [22]. Of note, the distribution among specific draining nodes was stochastic between subjects and the short imaging window likely precluded detection of secondary accumulation in organs such as the liver at later time points. Through branched DNA assay and the HALO ISH model, Hassett et al. showed that mRNA expression reached highest levels in the spleen at 854ng/g, followed by lymph nodes (155 ng/g), the injection site (98 ng/g), plasma (80 ng/mL), and liver (35 ng/g) in rats [24].

A remarkable mouse study tracing the fate of mRNA nanoparticles following delivery to a cell revealed that endosomal escape of LNP-mRNA results in the packaging up of the intact mRNA, along with the ionizable lipids, into small lipid particles that are then released as exosomes. These exosomes can then travel through the circulation to distant cells and transfect them with intact mRNA that can then be used to synthesize the encoded protein in the recipient cell. Thus, exocytosis serves as a secondary distribution mechanism as well as a clearance route. This study was published in 2019, and the delivered mRNA coded for human erythropoietin [25]. However, the same arguments should apply to the mRNA vaccines.

The ionizable cationic lipids, both in nanoparticles and the derived exosomes, may alter the zeta potential of blood components, potentially promoting coagulation [26–29]. Various cationic lipid formulations have been found to activate coagulation pathways. LNPs can bind to fibrinogen and induce platelet and thrombin activation; these effects are most notable in the lungs following intravenous administration in animal models. [30]. Such mechanisms could contribute to cases of thrombosis events following mRNA vaccination [31]. However, ionizable lipids, used in the approved mRNA vaccines, are designed to be neutral at physiological pH and any potential link between lipid components, inflammatory responses, and coagulation abnormalities requires further investigation. The metabolism and clearance of ionizable cationic lipids that become positively charged in acidic environments remain poorly understood.

Nanoparticles are not exclusively transported by immune cells. Recent human and animal data reveal that systemic circulation of mRNA-LNPs occurs and is far more dynamic than previously appreciated. In humans, Kent et al. quantified vaccine mRNA species and ionizable lipid SM-102 in serial plasma samples after boosting with a modRNA vaccine [32]. They found that both intact and fragmented mRNA decreased with nearly identical half-lives, suggesting that systemic clearance is primarily driven by the behavior of lipid-associated complexes rather than free RNA. Ren *et al.* later demonstrated rapid LNP-lipoprotein exchange after injection, with serum proteins forming transient hybrids (HDL in particular) that decoupled mRNA and lipid kinetics [33]. While the ionizable lipid SM-102 was nearly cleared from plasma within 24 hours, a small fraction of mRNA remained detectable for days, likely representing dynamic LNP disassembly and systemic removal rather than the persistence of intact particles in plasma. The remodeling of vesicles and exosome-like intermediates identified by Ren et al. support Luo et al. [34], whose single-cell mapping traced fluorescent LNPs and translated modRNA cargo to non-lymphoid targets such as endothelial cells in the heart, accompanied by immune-vascular proteomic shifts.

Together, these studies suggest a transformational sequence from local injection-site release and drainage into lymph nodes to systemic redistribution and plasma reconstruction, in which ionizable lipid chemistry, corona composition and clearance pathways collectively govern where and how transfection and subsequent modRNA translation occur in vivo.

J Di et al. demonstrated (via intramuscular injection in rats) that lymphatic uptake is the major route prior to entering the systemic circulation and subsequently reaching diverse tissues (but not exclusively) depending on their size [35]. Interestingly, the authors demonstrated that the mRNAs were detected in individual hepatocytes lining the liver sinusoids, whereas in the lymph node, they appeared highly concentrated, and the authors concluded that only released mRNAs might have been stained, whereas those encapsulated within LNPs were likely not detectable. They also found consistent detection of both LNPs and mRNA in circulation, supporting the findings of Kent et al. [32].

Furthermore, LNPs can transfect a variety of immune cells in the bloodstream, such as dendritic cells and macrophages [36]. They can also exit the circulation through fenestrated endothelium or transcytose into different tissues depending on the route of administration and the specific LNP formulation, then circulate there as they are exocytosed after initial cellular uptake [12]. Lipid nanoparticles also induce oxidative stress, which can enhance the release of exosomes (containing the cargo and cationic ionizable lipids) into the external environment and their circulation throughout the body [37].

Wei et al. compared four LNP formulations, Onpattro-like (DI-8), Onpattro-like (Alnylam), Moderna, and Pfizer/BioNTech-like, and observed differences in systemic leakage of the labelled mRNA into the circulation at 12 hours. Less leakage was observed with the more stable Onpattro[®]-like (DI-8) formulation (13.9%) than with the Moderna formulation (31.4%) [38]. Based on these observations and others [25,32,33], we propose that LNPs exhibit various levels of uptake, remodeling in the systemic circulation, transfection, and exocytosis that depend on the formulation, route, and other factors, which occur simultaneously and are overlapping in nature. Moreover, Balcorta et al. demonstrated that conventional radiotracing and fluorescent labelling approaches lack the subcellular resolution required to map LNP distribution accurately [39]. They introduced new peptide based tags that enable reliable visualization of LNP trafficking within cells and tissues. This innovative approach, termed SPARKLE (Strategic Peptide Anchored, Retained, and Kept after Lipid Elimination), leverages lysine-rich peptide sequences conjugated to LNPs via maleimide chemistry, ensuring signal retention even after lipid-disrupting processes like delipidation or tissue clearing for precise subcellular and 3D tracking.

Building on these observations, we analyze the transfection process associated with LNP formulations in greater detail and provide a mechanistic framework that underlies the adverse effects observed with these vaccines. In the following sections, we examine the transfection process mediated by LNP formulations and demonstrate that it contributes substantially to the adverse effects documented with these vaccines. We propose a perspective that can explain the heterogeneous and seemingly idiosyncratic adverse events observed following modRNA–LNP vaccine administration over the past 4-5 years [40–44]. In this work, we will consider the basic perspective that LNPs do not act as simple carriers of the modRNA payload but exhibit complex, diverse pharmacodynamic and biological effects.

Several peer-reviewed analyses have characterized post-authorization adverse events associated with the mRNA vaccines, notably myocarditis, neuropathic, and inflammatory responses [45–47]. Independent clinical registries have compiled patient-reported outcomes and case documentation that expand the empirical understanding of post-vaccination effects. These data highlight the variability of systemic reactions and motivate deeper inquiry consistent with the LNP-driven perturbation framework proposed here.

The mechanism of action and possible persistence of LNP components, combined with their capacity to release modRNA into the cytosol, result in prolonged cellular stress responses and inflammation. Subsequent translation of the modRNA can lead to high local and systemic levels of spike protein, further amplifying these stress responses and promoting sustained innate immune activation. In this context, the spike protein should be considered primarily as an amplifier and self-assembling driver of these events, since it may be produced in diverse transfected cell types and can circulate differently than after natural infections. Furthermore, subsequent viral exposure after these

changes can unpredictably lead to further alterations in the immune response, compounding prior membrane-level dysregulation.

2. Lipid Nanoparticles for mRNA Delivery: Biological Properties and Effects on Cellular Systems

Before we can establish our hypothesis, the pharmacological and biological aspects of LNPs must be examined in more detail.

2.1. Factors Influencing Nanoparticle Bioactivity

Nanoparticles' high surface area gives LNPs unique properties that influence interactions with proteins and cells, affecting uptake and immune responses. Their behavior depends on the combined physicochemical characteristics of the entire particle, including size, charge, shape, lipid composition, and packing (payload), rather than on individual lipids [48]. Factors such as lipid unsaturation, branching, payload, encapsulation, stability, and impurities all impact membrane fusion, biodegradability, persistence, safety, and effectiveness [49]. The structures of COVID-19 mRNA-LNPs remain unclear due to self-assembly and lipid properties. Models vary from multilamellar vesicles with blebs to core-shell structures [50,51] with estimates indicating that 12% [52] to 80% [53] of LNPs lack mRNA, depending on assay and formulation [54].

In vivo, a biocorona forms when the LNPs contact biological fluids, creating a dynamic and diverse coating of serum proteins primarily composed of lipoproteins, immunoglobulins, albumin, complement, and coagulation factors that confers a distinct biological identity. It varies by species [55], and is determined by both LNP characteristics (size, charge, PEG density, rigidity) and host or environmental factors [56]. In humans, it remains incompletely defined, with ApoE, vitronectin, C-reactive protein, and alpha-2-macroglobulin consistently present [57]. The protein corona can modulate ligand accessibility and cellular interactions, with ApoE binding shown to alter LNP structure, biodistribution, and modRNA stability [58]. LNPs remodel in plasma and lymph, involving lipid and protein transfer, fusion with endogenous particles, and PEG desorption [59]. These changes can influence nanoparticles' stability, target cell specificity, immune recognition, and biodistribution, influencing their effectiveness and possibly increasing the risk of adverse effects [20].

2.2. LNP Biodistribution

With these distinctions in mind, it is essential to consider the distribution of LNPs throughout the body and the cell types they encounter, as these factors influence uptake, antigen presentation, and downstream cellular responses. Biodistribution refers to the physical location of LNPs or drugs within the body and does not necessarily indicate cell entry. Transfection involves the uptake and endosomal escape of nucleic acids into cells. Gene expression occurs when intact modRNA is translated into protein, depending on ribosomal activity and protection from degradation. These separate steps are often conflated in studies and regulatory submissions.

Animal models, primarily rat studies, show that LNPs distribute widely because of their physicochemical properties and the formation of a biocorona, primarily accumulating in the liver, spleen, and draining lymph nodes, which are rich in phagocytic cells of the reticuloendothelial system (RES), involving macrophages and monocytes, Kupffer cells, and splenic macrophages [60]. Hepatocytes are also primary targets, aided by ApoE in the biocorona and liver fenestration. LNPs also reach the spleen and lymph nodes, where uptake by macrophages and dendritic cells supports antigen presentation and enhances the effectiveness of modRNA vaccines. Additional "off-target" accumulation occurs in the heart, lungs, adrenal glands, ovaries, eyes, and other tissues, facilitated by transcytosis or direct penetration [61–63]. Targeted cell types include epithelial, endothelial, and basal cells, as well as cardiac and skeletal muscle, bone marrow-derived immune cells, and hepatic stellate cells, highlighting the widespread biodistribution of LNPs [3,64–66].

The route of administration also affects the biodistribution of LNP-modRNA therapy. SARS-CoV-2 mRNA vaccines are given intramuscularly. Factors such as syringe pressure, perfusion rate, proximity to blood and lymphatic vessels, local pH, and temperature influence this process [67]. A European Medicines Agency assessment report summarized the process as follows: “Intramuscular administration of LNP-formulated RNA vaccines results in transient local inflammation that drives recruitment of neutrophils and antigen-presenting cells (APCs) to the delivery site. Recruited APCs can take up LNPs and express the spike protein of SARS-CoV-2 through translation, then migrate to nearby lymph nodes where T cell priming occurs” [68]. Kent *et al.* demonstrated in humans that the ionizable lipid, quantified via mass spectrometry, and the vaccine modRNA, quantified by qPCR, appear in circulating plasma, peaking between 4 hours and 2 days post vaccination [32], while Buckley *et al.* visualized comparable rapid trafficking to draining lymph nodes in non-human primates using PET-CT but did not measure plasma kinetics [22]. Together, these findings indicate that intramuscular administration establishes an early lymphatic and vascular distribution phase that initiates immune activation before systemic clearance.

2.3. Mechanisms of Uptake

Uptake occurs via both receptor-mediated and receptor-independent mechanisms, often simultaneously, with the protein corona modulating these interactions [69,70]. Receptor-independent uptake relies on nonspecific hydrophobic or electrostatic forces, while receptor-mediated pathways, including clathrin-mediated endocytosis, are dependent on the local microenvironment and lipid-membrane interactions. Specific lipid components, such as helper lipids, can alter membrane conformation and signaling to facilitate G-Protein Coupled Receptor (GPCR) engagement without direct binding, and lipoprotein-enriched coronas further enhance internalization [13]. Successful delivery requires release of the modRNA into the cytosol, a process termed transfection, which is a critical step in intracellular delivery [71]. Organ fenestrations and LNP apparent pKa primarily govern biodistribution and uptake, while the zeta (ζ) potential influences protein corona formation [72] (see **Figure 1**). Given the diversity of mechanisms, receptors, and cell states within complex biological systems, systematically targeting receptor-driven and/or non-receptor-driven pathways remains highly problematic [63]. The key challenge is not whether transfection occurs, but how much it occurs and how it is affected by systems biology, and vice versa.




Figure 1. TOP: Schematic representation of the physicochemical and biological characteristics of an mRNA-loaded lipid nanoparticle (LNP). The nanoparticle is composed of four principal lipid constituents: PEGylated lipid (blue), DSPC (green), an ionizable lipid (pink), and cholesterol (purple). These components self-assemble into a quasi-bilayer structure, forming ionizable-lipid-rich domains that complex with the mRNA cargo (black). Following administration, and under physiological conditions (pH7.4), approximately 10% of the ionizable lipid headgroups are protonated, depending on the lipid's apparent pKa, approximately 6.1 (ALC-0315) to 6.7 (SM-102). **BOTTOM:** Following exposure to plasma, serum proteins and antibodies rapidly adsorb onto the LNP surface, forming a protein corona (shown in blue, orange, and gold) that, together with surrounding counterions, **electrostatically shields** the internal positive potential, producing an apparently neutral surface (near-zero zeta potential measurements). Red plus signs within the particle represent the hidden electrostatic potential that fades in density toward the corona, indicating charge attenuation through the lipid shell and adsorbed proteins. This internal-external charge asymmetry influences serum stability, biodistribution, and cellular uptake and contributes to endosomal escape behavior. **Created in BioRender. Seger, F. (2025)** <https://BioRender.com/mjhdche>.

2.4. Endosomal Escape and Membrane Destabilization Due to Ionizable Lipids

For LNPs carrying modRNA, successful endosomal escape is essential for therapeutic action. After endocytosis, the acidification of endosomes protonates ionizable lipids (e.g., ALC-0315, pKa ~6.1; SM-102, pKa ~6.7), promoting lipid rearrangement, membrane destabilization, and the release of the payload into the cytosol through proton-driven osmotic swelling, also known as the proton sponge effect [71,73]. Endosomal damage, evidenced by galectin recruitment, can occur solely from ionizable lipids without cytosolic RNA delivery [74]. Smaller membrane perturbations induced by LNPs are detected and sealed by the Endosomal Sorting Complexes Required for Transport-III (ESCRT-III) machinery. Lipid geometry, such as the conical shape of branched, unsaturated fatty acids, further induces negative curvature stress that facilitates membrane destabilization [75]. Computational and experimental studies suggest that LNPs can transiently tear membranes, disrupt lipid raft organization, and tether to the endosomal membrane, enhancing escape [74,76,77].

Endosomal escape is highly inefficient, as only approximately 1–15% of internalized LNPs result in gene expression or spike protein production, due to the brief fusion window, typically within minutes after cellular uptake, during endosome maturation [71,78–81]. LNPs that fail to escape are degraded via lysosomal fusion or exocytosed, making endosomal escape a primary bottleneck in modRNA delivery. If modRNA is not released into the cytoplasm, endosomes mature and fuse with lysosomes, where enzymatic degradation of modRNA and lipids occurs; however, accumulation of LNP components can impair lysosomal function, block receptor recycling, create a cellular “traffic jam,” and prolong lipid retention, reducing therapeutic efficacy and potentially causing toxic effects [71,82–85].

Indeed, LNP uptake follows a bell-shaped, nonlinear response influenced by the LNPs themselves and cell-specific factors. Immune cells such as monocyte-derived macrophages and THP-1 cells exhibit limited cytotoxicity compared to other cell types, likely because their phagocytic and endocytic pathways better manage LNP uptake and membrane stress [86]. This has implications for cell signaling, which is itself a highly dose-dependent process [87].

2.5. Spread to Distant Sites via Exosomes

Once modRNA escapes the endosome, it can be packaged into naturally secreted membrane-bound vesicles along with ionizable lipids and intact mRNA. These exosomes circulate systemically, transfect distant cells, and enable protein translation, as demonstrated in mice with erythropoietin in 2019 [25]. In humans, BNT162b2 vaccination induces exosomes carrying spike protein prior to antibody development [88], and spike-positive exosomes have been identified in cell supernatants [89], indicating that LNP cargo can redistribute beyond initial target cells and influence systemic protein expression and immune activation. The data suggest that endosomal escape allows modRNA

to enter exosomal pathways in a paracrine manner [90], facilitating the transport of both mRNA and ionizable lipids to distant secondary sites where functional translation is possible.

2.6. LNP Metabolism Leads to Oxidative Stress and Signaling Cascades

The process by which the LNPs disassemble and are metabolized within cells is not well understood. The metabolism of the ionizable lipid is typically described as hydrolysis and clearance [91,92], and their fatty acid metabolites can induce toxicity by activating peroxisome proliferator-activated receptors (PPARs) [84].

Additionally, lipid adduct formation poses an underrecognized risk. Tertiary amine-based ionizable lipids can generate N-oxides and reactive aldehydes during manufacturing and storage, which may covalently modify modRNA, rendering it untranslatable. Moderna first identified such adducts in 2021 [93] and noted that Tris buffer mitigates their formation [94]; Pfizer subsequently adopted Tris in late 2021 [95], raising the possibility that early batches may have been more vulnerable. Upon inoculation, damaged adducted modRNA taken up by cells could be recognized as abnormal or viral-like, possibly triggering inflammatory and interferon responses [16,96]. Additionally, reactive aldehydes like 4-HNE from lipid peroxidation are cytotoxic, can disrupt protein folding, generate neoantigens, and promote oxidative stress and lysosomal dysfunction [84,97,98]. However, direct in vivo evidence for such processes is lacking.

Developers have tested alternative lipids and mitigation strategies [99], but the long-term persistence [92], biodistribution [100], and possible mutagenic risks [101] of ionizable lipids remain poorly understood. In silico studies suggest these lipids may localize within the bilayer [74,75], further complicating predictions of LNP stability and in vivo behavior. This is important because, intracellularly, the lipid nanoparticles provoke an immune response that induces the release of reactive oxygen species (ROS) [101]. Although present at low levels, RNA-lipid adducts could plausibly influence translation or stress signaling, and the chemical stabilization of modRNA raises the question of whether such lesions might persist in cells longer than expected. This has not been systematically investigated.

Because mRNA modified with N1-methylpseudouridine can persist in lymph node germinal centers for up to 8 weeks post vaccination [18,19], it remains worth considering whether lipid-RNA adducts influence its persistence. Similarly, residual bacterial DNA impurities from manufacturing could also form DNA adducts, which could also stimulate an immune response, leading to increased inflammatory signaling [102]. Therefore, LNP metabolism should be seen not only as producing degradative metabolites but also as a source of bioactive and potentially pro-inflammatory lipid species with lasting biological effects.

2.7. Activation of the Immune System

LNPs can activate the innate immune system in plasma by transfecting immune cells, providing an intrinsic adjuvant-like activity [85] that aids in antibody production; they can also trigger severe, even life-threatening, adverse reactions. An IgE-mediated allergic reaction can occur via induced IgE antibodies to PEGylated particles on the biocorona [5–7]. CARPA can occur due to anti-PEG IgM antibodies, inducing mast cell activation and the release of histamines [8], leading to acute infusion reactions [103]. Allergic reactions observed after modRNA COVID-19 vaccination may be mediated by this phenomenon [104].

While RNA-lipid adducts and residual DNA may affect the persistence of modRNA and immune signaling, the clinically approved siRNA-LNP patisiran (Onpattro®) provides a clinical reference model in humans. Although its ionizable lipid is less biodegradable [91], endosomal escape is limited (~1%), with transient membrane disruptions, which contribute to slower and decreased cytotoxicity [86]. Clinically, Onpattro infusions can trigger CARPA, sometimes severely, through complement activation [105,106]. However, its hepatotropic biodistribution limits off-target effects to the liver, where mild and generally reversible hepatic enzyme elevations have been observed, possibly reflecting underlying hepatocellular stress that could be masked by PPAR α [107] and

PPAR γ [108,109] activation, consistent with the known anti-inflammatory and metabolic modulatory effects of these receptors observed in renal epithelial cells and in complement factor D-mediated metabolic pathways (see also Section 4).

LNPs can activate TLR3, 7, 8, and 9 [110] in the endosome. Additionally, LNPs bind to diverse cell membrane receptors like CRP, TLR4, and TLR2, and can activate NLRP3 [111]. Moreover, they can also get directly internalized by macro-pinocytosis [112]. Recently, Baimanov et al. [113] found anti-PEG antibodies within the LNP corona, and observed complement opsonization that triggered CSF2RB-mediated phagocytosis by human myeloid cells in vivo, which suggests the protein corona itself may underlie immune responses to PEGylated lipids.

More broadly, proteins such as ApoE can adsorb to LNPs and engage receptors like LDL-R [114], exemplifying the complex interaction of LNPs on cell membrane uptake. These immune effects emphasize the importance of distinguishing between biodistribution, transfection, and gene expression, and show that LNP-modRNA interactions are nonlinear and highly context dependent, with the potential to produce pathogen-like effects that extend beyond simple cytotoxicity.

3. The Principles Behind How LNP-modRNA Was Thought to Work

The original idea behind modRNA technology arose from the problem that mRNA is immediately recognized by the immune system, in particular by intracellular toll-like receptors (TLRs), triggering an immune response that leads to rapid degradation of the mRNA before it can translate into protein [115]. To avoid these effects, teams such as Karikó and Weissman sought solutions to the issues of increased premature degradation and poor protein yield [116]. The thought was to suppress cytosolic pattern recognition receptors (PRR) such as the TLRs to avoid an immune response early on [117]. It was further assumed that, by suppressing TLR activation through specific nucleoside modifications such as N1-methylpseudouridine, and thereby increasing translation efficiency, these issues could be overcome [118].

However, it was not taken into account that transfection agents such as Lipofectamine can already promote immune stimulation [119–121]. Lipid nanoparticles and modified RNA both act directly on the cellular sensing machinery. Moreover, the activation of dendritic cells and monocytes through pattern recognition receptors such as TLR2, TLR4, and TLR7/8 initiates a TBK1–IRF7 signaling axis that drives innate immune programming [122].

In a recent in vivo model, it was shown that LNPs alone can drive strong reactogenicity and sickness behavior in mice via TLR4 and MyD88 [123]. Furthermore, there is growing evidence that TLR engages in crosstalk with other immune receptors, and this itself is decisive for the downstream outcome [124–128]. For example, it was shown that TLR-TLR crosstalk in human peripheral blood mononuclear cells (PBMCs) elicits both synergistic and antagonistic effects on the regulation of type I and type II interferons, IL-12, and TNF- α [129].

Furthermore, TLRs participate in context-specific crosstalk with other receptors, such as members of the LDL receptor family [130–132]. As suggested by the recent review by Gutschli & Seger [12], LDL receptors play an important role in the uptake of LNPs [12]. Hovland et al. [131] also indicate that both LDL and the complement system, as well as TLRs, are crucial players in the development of atherosclerosis. Moreover, TLRs engage in crosstalk with membrane lipids [133,134].

This may create a paradox when attempting to elicit an adequate immune response through LNP-modRNA injections. On the one hand, cytosolic TLRs are intentionally silenced or even suppressed, while at the same time TLR4 is activated. Moreover, macropinocytosis-like and endocytotic uptake occur in an uncontextualized manner, potentially leading to receptor internalization and/or activation. It appears biologically plausible that the cascade underlying this paradox originates at the membrane level during transfection, leading to profound downstream alterations in cellular signaling, transcriptional profiles, and ultimately protein processing.

To test this hypothesis, we will first examine the limited omics data currently available to determine whether the cell membrane is affected and whether diffuse changes at the transcriptomic and proteomic levels occur, as would be expected if a broad, nonspecific response takes place. In the

final section of this work, we will then propose a mechanistic perspective on disturbances in all the cellular lipid membranes that could result from exposure to the lipid nanoparticles.

4. Omics: Evidence for Membrane Dysfunction Secondary to LNP Transfection

Omics-based methodologies, including transcriptomics, metabolomics, lipidomics and proteomics, serve as exploratory tools for investigating cellular and organismal responses under defined experimental conditions. Rather than providing conclusive mechanistic proof, these approaches generate high-dimensional datasets that facilitate the identification of molecular patterns, pathway perturbations, and candidate mechanisms. In this sense, omics data provide a critical foundation for formulating and testing hypotheses, as their value lies not in definitive causal attribution but in enabling falsifiability through reproducible molecular signatures.

In order to investigate the intracellular processes potentially triggered by modRNA-based COVID-19 vaccination, omics evidence offers a useful framework for examining the molecular signatures associated with both empty LNPs and modRNA-loaded LNPs in immune cells. Shotgun omics approaches enable a broad mapping of the diverse signaling cascades that may follow LNP uptake, endosomal processing, and subsequent modRNA translation. These datasets, while descriptive in nature, provide starting points for mechanistic interpretation, and they thus serve as a basis for determining if membrane dysfunction occurs as a result of LNP transfection (L-DMD).

To the best of our knowledge, very few omics analyses have been conducted on the effects of the lipid nanoparticles, and none have directly compared vaccinated and unvaccinated cohorts over longer periods of time. In particular, transcriptomic, lipidomic, and proteomic studies are of primary interest, as they offer the most direct insights into altered signaling pathways and protein activity states in immune cells following LNP and modRNA transfection.

4.1. Ndeupen et al. - a Pioneering Omics Study

In 2021, Ndeupen et al. published a pioneering in vivo study, in which they provided an analysis of how a biological system reacts to empty LNPs (eLNPs) [135]. Their pharmacokinetic investigation, in which wild-type (WT) C57BL/6 (B6) mice were intramuscularly injected with 10 μ g of eLNPs, revealed thousands of changes in gene expression patterns [135]. The choice of dosage corresponds to the typical design for pharmacodynamic evaluation [136,137].

The study analysis revealed that “with $p < 0.05$ and FDR [False Discovery Rate] < 0.05 , 9,508 genes and 8,883 genes, respectively, were differentially expressed.” A marked upregulation of genes involved in monocyte and granulocyte development, recruitment, and function (e.g., CCL2, CCL3, CCL4, CCL7) was observed. Gene set enrichment analysis (GSEA) revealed a pronounced induction of inflammatory cytokines, including IL-1 β , GM-CSF, and IL-6, which are hallmark markers of acute immune activation.

Table 1 displays some of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that were either up- or down-regulated in response to the lipid nanoparticles. NF- κ B was upregulated by 2.5–2.6 \log_2 -fold. In contrast, the TCA cycle and PPAR signaling pathways were markedly downregulated, with an approximate 2.0 \log_2 -fold reduction in expression. The upregulation of genes associated with TLRs, NOD-like receptors, and RIG I-like receptors suggests a robust systemwide immunological response. Hematopoietic cell lines, in particular, showed a more than 2 \log_2 -fold increase in gene expression, indicating pronounced activation within stem and progenitor compartments that may be driven by the combined signaling of TLRs, NOD receptors, and RIG I pathways and/or the internalization pathways of the LNPs.

Table 1. KEGG pathways that were identified by Ndeupen et al. [135] as either up- or downregulated by LNPs, and the associated biological functions or consequences.

Pathway	Direction of NES	Consequences/Biological Function
Mismatch repair	Downregulated	DNA repair inefficiency; Promotion of tumorigenesis [138]
Phagosome	Upregulated	Induction of phagocytosis and autophagy
Necroptosis	Upregulated	Inflammatory form of cell death associated with many human diseases [139]
Apoptosis	Upregulated	Induction of programmed cell death
Metabolism of xenobiotics by cytochrome P450	Downregulated	Impaired cytochrome P450 activity in the liver may lead to increased drug toxicity [140]
NF- κ B	Upregulated	A key regulator of the immune system, inflammation, cell survival, and stress responses [141]
TNF	Upregulated	A powerful pro-inflammatory agent that regulates many facets of macrophage function [142]
IL-17	Upregulated	Promotes proinflammatory cytokine production, neutrophil recruitment, tissue remodeling, and antimicrobial defenses [143]
Toll-like receptors, RIG-1-like receptors, Nod-like receptors	Upregulated	These receptors activate inflammatory and immune responses [144]
TCA cycle	Downregulated	Impaired TCA cycle is a feature of Alzheimer's disease [145]
Circadian rhythm	Downregulated	Dysregulation of circadian rhythms increases cancer susceptibility [146]
Hematopoietic cell lineage	Upregulated	Increased clonal hematopoiesis leads to hematological malignancy [147]

4.2. Upregulation of Multiple Inflammatory Markers

The simultaneous upregulation of IL-6, IL-1 β , TNF α , and IL-17 is notable, since these cytokines form a pro-inflammatory axis frequently implicated in the pathogenesis of autoimmune and chronic inflammatory conditions [148]. While IL-6 can modulate autophagy in the context of oxidative stress [149], and IL-1 β levels may be influenced by autophagic clearance of pro-IL-1 β [150], their elevation in this setting more likely reflects a broader integration of NLRP3-inflammasome activation [149], NF- κ B signaling, and MAPK pathway dysregulation [151–153]. Similarly, β -chemokines such as CCL2, CCL3, CCL4, and CCL7 contribute not only to immune cell recruitment [154,155], but may also intersect with autophagy-related transcriptional regulation (e.g., via FOXK1) [156,157]. These mechanisms, in concert, could promote maladaptive immune activation and, under chronic conditions, create a milieu favoring autoimmunity or other pathogenic sequelae.

Interestingly, Forster III et al. [158] demonstrated that lysosomal disruption triggers the NLRP3 inflammasome cascade, implicating potential p38-MAPK dysregulation, as previously reported by Shin et al. [159] and shown by Lv *et al.* [160]. These findings align with the increased phagosome-related expression changes observed by Ndeupen et al. [135].

4.3. Downregulation of PPAR and AMPK Signaling

The data of Ndeupen et al. show downregulation of both PPAR pathways and AMPK signaling [135]. Given that PPAR γ is a central regulator of lipid metabolism, mitochondrial function, and anti-inflammatory signaling and is modulated through AMPK-dependent phosphorylation [161,162], the strong downregulation suggests disruption of homeostatic lipid and energy control. Such suppression, as reported under inflammatory or stress conditions [163–165], may exacerbate NF- κ B activation (as shown by the data) and contribute to chronic inflammatory or degenerative outcomes. The expression pattern is indicative of MAPK pathway dysregulation that affects PPAR γ phosphorylation and signaling [164,165]. Notably, in macrophages, PPAR γ regulates inflammatory gene expression [164]. Ballav et al. highlight that partial PPAR γ dysregulation can broadly disturb cellular metabolism and signaling, influencing disease fate decisions across multiple tissues [166].

4.4. Downregulated Xenobiotic Metabolism by Cytochrome P450 Enzymes

Another notably downregulated KEGG pathway identified by Ndeupen et al. was the metabolism of xenobiotics by cytochrome P450 (CYP) enzymes [135]. Approximately 80% of all drugs are mainly metabolized by CYP isoforms belonging to the CYP1, 2, and 3 families, which are primarily expressed in the liver [167]. Because CYPs are among the most diverse catalysts in biochemistry, they contribute to variations in drug responses among individuals, influenced by genetic and epigenetic factors, environmental elements such as gender, age, and disease, as well as pathophysiological aspects. Significantly, CYPs can be inhibited or induced by other drugs and metabolites, drug-gene interactions, and by inflammatory cytokines.

CYP enzyme downregulation tends to correlate with rises in pro-inflammatory cytokines, including IL-6, TNF- α , IFN- γ , IL-2, IL-1 α , and IL-1 β [168]. In fact, inflammatory cytokines such as IL-6, TNF- α , and interferon- γ induced by both infection and vaccination have been shown to suppress multiple hepatic CYP isoenzymes, most notably CYP1A2, CYP2C19, CYP2C9 and CYP3A4 [169]. For the modRNA vaccines, case reports and cohort analyses document clinically relevant changes in clozapine pharmacokinetics post vaccination, in some cases leading to neutropenia and hospitalization [170–172]. The mechanism is consistent with inflammation-mediated suppression of CYP enzymes, particularly CYP1A2 and CYP3A4, central to clozapine metabolism [173]. Comparable effects have been reported for other CYP metabolized drugs, including statins, benzodiazepines, antiepileptics, and immunosuppressants, which are predominantly CYP3A4 [174] or CYP2C9 substrates [175].

Transient suppression of these pathways could significantly alter drug exposure, due to the robust innate inflammatory response following modRNA vaccination. Pharmacokinetic interactions studies specific to modRNA vaccines remain scant, and clinicians might be unaware of these potential dynamics. Furthermore, recent findings suggest that the aryl hydrocarbon receptor (AhR) and PPAR γ regulate CYPs in crosstalk via mTORC1 [176] indicating that inflammatory or metabolic stressors could simultaneously influence detoxification, lipid homeostasis, and cellular energy metabolism. CYP enzymes also perform crucial biological functions, including cholesterol and fatty acid metabolism, vitamin D activation, and the synthesis of prostacyclins and thromboxanes from arachidonic acid [177]. These pathways could likewise be perturbed following modRNA vaccination, though comprehensive studies have yet to be reported.

The magnitude of CYP downregulation observed following modRNA vaccination appears greater than would be expected from a conventional vaccine-induced inflammatory response. Clinically significant changes in drug levels due to cytokine-mediated CYP suppression have otherwise been observed predominantly in patients with severe systemic inflammation, such as sepsis, major trauma or critical illness, where C-reactive protein (CRP) levels often exceed 100 mg/L [178]. The observation of comparable pharmacokinetic perturbations in vaccinated individuals suggests that the inflammatory burden imposed by the modRNA platform may, in some cases, approach the intensity of these pathophysiological states [179]. Such a response to mRNA vaccination

suggests the need to characterize both the acute-phase intensity and resolution of post-vaccination inflammation, especially in those receiving drugs with a narrow therapeutic range.

4.5. Non-Canonical Transcriptomics and Proteomic Alterations – Are the TLR4 Reactions Decoupled?

The observations of Ndeupen *et al.* [135] are consistent with those made by Zelkoski *et al.* [9], showing that empty LNPs trigger TLR4-dependent signaling that bifurcates into a strong MyD88–NF- κ B response and a parallel, though weaker, TRIF-mediated IRF activation. Their KEGG GSEA analysis revealed that JUN, a component of the AP-1 transcription factor complex activated via the JNK-MAPK cascade downstream of TLR4–MyD88 signaling, exhibited a 1.93-fold \log_2 expression change, whereas the JAK-STAT axis, typically associated with interferon signaling, showed a more modest 1.13-fold \log_2 change. Taken together, the results by Ndeupen *et al.* and Zelkoski *et al.* show a biased TLR4 dual-pathway activation pattern which should be considered as divergent. These results suggest a decoupled TLR4 dual pathway activation, which is in line with the above discussed observations. Decoupling of the TLR4 pathway starts upstream at the cell membrane, and this potentially supports our L-DMD hypothesis.

Another study supporting this conclusion was published by Luo *et al.*, investigating proteomic alterations induced by lipid nanoparticles (LNPs) without mRNA cargo. The authors compared cargo versus no-cargo LNPs versus phosphate buffered saline [PBS] controls [34]. They detected 375 differentially expressed proteins (DEPs), of which 240 were upregulated and 135 downregulated in the no-cargo LNP group. These changes were linked to metabolic processes, particularly ribosome function, protein translation, and RNA metabolism, as determined by Reactome pathway analysis. Specific markers, including Ribosomal Protein (Rpl)11, Rpl15, Eukaryotic Initiation Factor (Eif) 4b, Eif2b3, Ribosomal Protein (Rps) 6, and Rps2, were found to be differentially regulated.

Driven by these data, we suggest that signaling transduction pathways such as mTORC and the MAPKs regulating the eucaryotic eIF family may be involved in transfection processes [180,181]. Furthermore, the study investigated interactions of different ionizable LNP lipids (MC3, Lung SORT, SM-102, and ALC-0315) with cell surface proteins to identify possible competitors for LNP attachment forming a proteinaceous corona. In this context, vitronectin and ficolin-1 were found to particularly facilitate attachment of LNPs to heart tissue cells. Interaction with vitronectin may promote cell proliferation and enhance tumor growth and metastatic potential [182], while ficolin-1, through binding to transforming growth factor (TGF- β 1), may modulate the lectin pathway and the complement component of innate immunity [183].

4.6. Dysregulation of MAPK/ERK, JAK-STAT, and Other Signaling Pathways

Knabl *et al.* conducted an *in vivo* transcriptomic study to assess the systemic effects of modRNA packaged in LNPs in both comorbid elderly and healthy younger vaccinated individuals [184]. In this study, four patients had received the first dose of BNT162b2 approximately 11 days before the onset of COVID-19 symptoms, while five patients were unvaccinated. All patients were treated with dexamethasone. Immune transcriptomes (MSigDB-GSEA) were analyzed at days 7–13, 20–32, and 42–60 after symptom onset (Supplementary 3). In the raw data, thousands of genes in the transcriptomics were statistically significantly changed (up- or downregulated) after the BNT162b2-application.

As reported by the authors, COVID-19 symptoms (Beta variant) developed in all patients including those who became infected shortly after the administration of the first BNT162b2 dose [184]. MSigDB-GSEA analysis of the four vaccinated patients revealed acute gene expression changes across thousands of genes. One of the elderly comorbid patients died before the end of the study. Signaling pathways that were affected included JAK-STAT3, Interleukin-6 (IL-6) and Kirsten Rat Sarcoma (KRAS) (part of the ERK-MAPK pathway), among others, with many changes reaching statistical significance.

The canonical ERK-MAPK signaling pathway involves several key components: Rat Sarcoma (Ras), Rapidly Accelerated Fibrosarcoma (Raf), Mitogen-Activated Protein Kinase (MEK), and

Extracellular Signal-Regulated Kinase (ERK), and it has extensive crosstalk with the mechanistic target of rapamycin complexes (mTORC) 1/2 downstream [185,186].

Notably, tumor necrosis factor alpha (TNF- α) via NF- κ B signaling was upregulated in both study groups (see next paragraphs), similar to the activation observed by Zelkoski et al. [9] and Ndeupen et al. [135]. While it remains unclear whether this reflects canonical (RELA/p65-I κ B-dependent) or non-canonical (NIK-RELB-mediated) NF- κ B activation [187], such induction is consistent with stress-responsive transcriptional reprogramming. In this context, KRAS activation is of particular concern, as RAS-driven signaling can trigger both NF- κ B pathways through the RAF-MEK-ERK and PI3K-AKT cascades, thereby promoting cellular adaptation to inflammatory or genotoxic stress and, under chronic conditions, favoring malignant transformation [188,189]. Concurrent upregulation of p53, as also reported by Knabl *et al.*, indicates the presence of a counter-regulatory response to such proliferative or stress-related cues [190].

Moreover, Knabl et al. detected significant mTORC1 signaling across doses 1 to 3, with ten overlapping genes reaching statistical significance, underscoring that both mTORC1 and p53 are co-activated under conditions of physiological and genotoxic stress. KRAS signaling can engage NF- κ B through multiple downstream routes (including RAF/MEK/ERK and PI3K/AKT branches) [141], thereby promoting transcriptional programs that support cell survival and stress adaptation. Distinguishing canonical from non-canonical NF- κ B activation in these samples requires targeted inspection of pathway components (e.g., RELA/p65 phosphorylation and I κ B degradation for the canonical arm; NIK/RelB dynamics for the non-canonical arm) at the transcript and protein level [141,187]. Moreover, the four elderly patients showed profound upregulation of the JAK-STAT5 pathway with IL-2 and the JAK-STAT3 pathway with IL-6.

The authors later included eight healthy naive individuals receiving their first vaccine dose, analyzing transcriptional changes 7-10 days post-vaccination. In these naive individuals, selective upregulation of the transcription factor E2F8 and specific interferon-stimulated genes was observed, while E2F1 and CCNA1 remained largely unchanged. Similarly, only three canonical mTORC1 target genes (CDC25A, RRM2 and BUB1) were modulated, indicating that global mTORC1 activation was minimal but statistically significant at this early time-point. CDC25A, RRM2, and BUB1 mark the transitions G1/S (CDC25A), DNA synthesis (RRM2), and mitosis (BUB1) [191]. However, growing evidence suggests that E2F1/2/4 expression correlates with immune cell infiltration and may modulate immune responses in proliferative or stressed cells [192–194].

It is known that E2F1 is in tight crosstalk during cell cycle phases with the 7 other members of the E2F transcription factor family [195–197]. Furthermore, it was shown that E2F1 plays a crucial role in immune cell differentiation and cloning [198,199]. These findings support the notion that modRNA-LNP exposure can induce selective, systemic transcriptomic changes even in the absence of active viral infection, with partial activation of cell cycle genes, interferon responses, and minimal mTORC1 signaling, consistent with a fragmented or dysregulated cell cycle program rather than a synchronized proliferative response [200,201]. Furthermore, the consistent P53 upregulation in both groups together with a decoupled E2F1 from E2F8 transcription factor transcriptome is indicating that a cell cycle dysfunctionality was observed in the immune cells which was depending on the mTORC1 signaling regulating CDC25A [202,203]. Another indication that the cell cycle is affected at the transcriptomic level is the coordinated enrichment of gene sets associated with mitosis, checkpoint control, and Rho-GTPase signaling (Supplementary Data 5). All analyses were made with KEGG and show that the signals were active.

In summary, the insights of Knabl et al. [184] support the assumption that the inflammatory properties of LNPs observed in mice by Ndeupen et al. and the findings of Luo et al. are also present in vivo following BNT162b2 transfection. As discussed in the previous section regarding TLR signaling and the counterintuitive effects of modRNA modifications, these effects may be additive and/or synergistic and/or antagonistic in vivo. Moreover, as discussed in Section 2, not every immune cell internalizes LNPs equally, as uptake efficiency is influenced by factors such as the protein corona.

This heterogeneity highlights limitations in generalizing the transcriptomic effects observed in Knabl et al. [184] and sets the stage for the subsequent discussion of more controlled experimental models.

4.7. Further Studies Using Single Cell Analyses Revealing Gender-Based Differences

In this context, another KEGG GSEA analysis by JD Knapp and A Bhargava on a single-cell basis provides an important complementary perspective on the sex-specific transcriptomic responses following BNT162b2 LNP-modRNA administration [204]. The authors analyzed healthy individuals with a confirmed history of SARS-CoV-2 infection and demonstrated that T cells and monocytes displayed the most pronounced sex-linked genomic differences, including a high number of dimorphic genes.

Beyond immune-cell-type specificity, hematological sex differences were also evident: platelet counts differed significantly between females and males (3.6 % vs. 1.8 %) already before vaccination and diverged further after the first dose. Interestingly, there were no significant changes observed after the second dose (7.2% vs 7.3%).

On the transcriptomic level, the most substantial dimorphisms were observed in members of the MAPK family, notably MAPK6, MAPK8, MAPK1IP1L (upstream interactor; interacts for example with ERK1), and MAPKAPK5 (downstream effector of p38-MAPK), as well as in MAPKAP1 (SIN1), a scaffold protein that connects mTORC2 to the MAPK cascade via PI3K activation [204]. Concerning the SIN1 gene differential response, Ezine, Lebbe & Dumaz write in the abstract: "Moreover, the numerous interactions of SIN1 inside or outside mTORC2 connect it with other signaling pathways, which are often disrupted in human tumours such as Hippo, WNT, Notch and MAPK." [205], p. 1.

Furthermore, in addition to the above clinical studies, Hickey et al. conducted one of the first proteomic analyses examining molecular alterations following BNT162b2 and mRNA-1273 vaccination. Their data indicate that even one month after BNT162b2 administration, RAS-mediated signaling remained moderately downregulated [206]. The authors also observed a downregulation of RAS variant signaling, while the chemical carcinogenesis pathway appeared activated. This pathway encompasses several receptor-driven cascades, including ERK, PI3K/AKT/mTOR, and related signaling routes, which are normally involved in cellular adaptation processes and stress responses.

These findings warrant attention, as physiological RAS signal cascades act as finely tuned molecular switches that cycle between inactive and active states and back again over a defined temporal window, ranging from hours to a few days, depending on the cellular context [207–209]. Through these transient activation patterns, RAS-dependent signaling governs essential cellular functions such as migration, proliferation, differentiation, survival, and metabolic regulation [210,211]. Sustained alterations in these pathways, therefore, may reflect a broader disturbance of regulatory homeostasis rather than a direct oncogenic transformation. Nonetheless, a paradigm shift is occurring in this field of research, suggesting that cell homeostasis is one of the most important factors for cancer progression, challenging the traditional mutation-centric picture [212,213].

4.8. Disruption of the ESCRT Circuit and Phosphatidylinositol Signaling

Another relevant observation reported in a proteomics study by Hickey et al. concerns a reduction in endocytic activity and a downregulation of the ESCRT circuit, both of which point toward an acute perturbation of the phosphatidylinositol (PtdIns) cycle [206]. This cycle is a central phospholipid regulatory pathway that coordinates membrane dynamics and endosomal trafficking [214–216]. It has been shown that the modRNA-LNPs induce membrane perturbations, which are detected by the ESCRT machinery, and small disruptions are quickly sealed before disruption accelerates and larger perturbations trigger galectin 9 repair [74,86].

This observation is also consistent with the review by Hurley *et al.* [217], which summarizes ESCRTs as central to cell membrane repair mechanisms and, beyond that, to the organelle transport system. Interestingly, ESCRTs appear to be cooperators and facilitators for ubiquitin-driven PtdIns [218]. The ESCRT disruption demonstrated by Hickey et al. [206] also coincides with the

downregulated PPAR γ pathway reported by Ndeupen et al. [135], as recent results suggest direct crosstalk between PPAR γ and ESCRT [219].

Our review of existing omics analysis reveals cell homeostasis affecting properties of LNPs that go beyond the traditional toxicological effects, particularly through their ionizable lipid components and, as we will discuss in our last section, DSPC and cholesterol as well. One limitation that should be considered is that there are no data available on the use of empty LNPs in humans alone. It is therefore unclear to what extent synergistic, additive, and antagonistic effects need to be considered. Simonsen and Schoenmaker et al. reported that only 30–50% of LNPs actually succeed in containing and delivering genetic material [220,221]. This is another important observation that strengthens our hypothesis. However, since these minimally loaded LNPs or eLNPs have been shown to exhibit greater fusogenicity, endosomal escape efficiency, and gene expression in vivo, it is possible these “empty LNPs” could engage or overload the ESCRT machinery, affecting endolysosomal homeostasis and downstream signaling [222].

However, in vitro and in vivo data demonstrate that lipid formulated constructs, such as liposomes and LNPs, disrupt cellular homeostasis by altering signal transduction pathways, receptor activation, and phosphorylation cascades [9,135,223–225]. An autophagy deficiency might also appear, triggering apoptosis as one of the moderate downstream consequences, underscoring the broader toxic impact of LNPs. This finding is of considerable significance, as the omics data we have discussed here and the shifts in signaling pathways cannot be attributed solely to the presence of modRNA and/or spike proteins.

4.9. Perturbations Originate at the Plasma Membrane and Disturb PtdIns Signaling Cascades

The sequence of events needs to be considered: the LNPs are taken up first (time point 0), after which the release of modRNA into the cytosol occurs only with marked delay. In fact, with release rates estimated at well below 10–15%, as suggested by Müller et al. [78], it appears far more likely that most of the modRNA remains inside the LNPs and is subsequently exocytosed again. Only after an additional delay does the fraction of modRNA that escapes become translated into spike protein. This can occur at a distant site from the injection, as we have pointed out in Section 2.

However, our hypothesis that LNPs drive the immune system’s first response and have effects on more than only the immune system is furthermore supported by the study of Connors et al., [122], who showed that empty LNPs induce activation and maturation of monocyte derived dendritic cells (MDDCs) and also upregulated CD40 expression, which led to recruitment of pro-TFH cytokines, key cytokines and chemokines. Furthermore, Qin et al. showed in mice that these effects have transgenerational immunological shifted consequences [225].

Taken together, the above discussed findings underscore the fact that the earliest perturbations following LNP exposure likely originate at the plasma membrane, with the phosphatidylinositol (PtdIns/PI) cycle as a central regulatory hub. Even subtle disturbances at this level could have cascading effects on lipid raft organization, receptor localization, and downstream signal transduction pathways, leading to transcriptional alterations and, as Hickey et al. [206] and Luo et al. [34] have demonstrated, proteomic consequences.

Establishing precise mechanistic patterns in vivo remains challenging, particularly in the absence of large, well-characterized cohorts stratified by age, vaccine type, dose number, batch, comorbidities, prior illnesses, and genetic predisposition. Early membrane-centered dysregulation, although not directly reflected in conventional blood values, may nonetheless set the stage for broader signaling alterations that we hypothesize as the initiating events for downstream cellular responses and potential dysregulations which will lead to paracrine and endocrine cascades [226].

Therefore, in the next section, we will examine membrane organization, focusing on lipid rafts, as well as endosomal-lysosomal and autophagosomal aspects, which are suspected to act as primary drivers of the dysregulations, namely PI3K/AKT/mTOR, JAK-STAT and MAPK cascades, observed here. We will propose a plausible biological mechanism for how LNP uptake interferes with cellular homeostasis via L-DMD.

5. Breaching the Plasma Membrane: Important Roles for Phosphoinositides

In Section 2, we outlined that LNP/modRNA complexes enter cells through both receptor-dependent and receptor-independent endocytosis-like processes, i.e., membrane breaching. It is further evident that LNPs can transfect a broad range of cell types, including B cells, T cells, macrophages, and dendritic cells. This suggests that receptor shifts may already occur at this stage, involving altered conformations, translocations, or similar rearrangements.

The membrane-uptake mechanisms of LNPs are well documented. LNPs are internalized into the cell by endocytosis (receptor-mediated) and macro-pinocytosis (receptor-independent) This is best confirmed in the literature by earlier work such as that of Panariti et al. [227], Voigt et al. [228], and current reviews such as those of Wang *et al.* and Gerelli [229,230]. In this section, we focus on the mechanisms of membrane structuring and recycling and how these processes, when influenced by modRNA LNP technology, may lead to unpredictable consequences for membrane integrity and the recycling system.

We propose that membrane penetration and direct interactions of ionizable lipids with the phospholipid bilayer and membrane-bound receptors could contribute to reorganization events, including changes in lipid raft stability, where receptor proteins such as GPCRs are embedded. Ermilova and Swenson [75] and Pilkington et al. [77] provide relevant insights to support this perspective. Notably, Ermilova and Swenson's free energy calculations of ionizable tertiary amine lipids indicated that both ALC-0315 and SM-102 can easily reside in the hydrophobic core of the lipid bilayer. This is consistent with observations, such as those by Wang et al. [229] and Aliakbarinodehi et al. [79]. Furthermore, Lavagna et al. [231] suggest that the size-dependent aggregation of hydrophobic nanoparticles within lipid membranes can induce pronounced local curvature, folding, and even transient phase transitions of the bilayer. These membrane reorganizations arise purely from nanoparticle geometry and concentration and could thus represent an initial mechanical trigger that perturbs phosphoinositide organization and receptor localization, setting the stage for altered signaling and recycling dynamics.

5.1. Brief Overview of the Phosphatidylinositide Cycle

Given that membrane interactions are evident, the membrane structuring and recycling process must first be examined by investigating the phosphatidylinositide (PI)-cycle and potential effects the LNPs may have on it. The eukaryotic cell membrane consists of a phospholipid bilayer forming a stable barrier between aqueous compartments [232]. Phospholipids are amphipathic molecules, with hydrophobic tails oriented inward and hydrophilic heads facing the aqueous environment. This arrangement allows selective transport of molecules. Membrane fluidity is influenced by fatty acid composition and cholesterol content. Embedded proteins, such as protein receptors (e.g., GPCRs), ion channels, and transmembrane-bound enzymes such as angiotensin converting enzyme 2 (ACE2), mediate transport, signaling, and cell-cell recognition via extracellular signaling [233]. The composition of fatty acids in phospholipids often follows the 18:0/18:1, or 18:1/18:1 rule, where the numbers indicate the degree of saturation. This affects membrane fluidity, as unsaturated chains (e.g., 18:1) reduce packing density and increase lipid mobility due to their kinks [234]. Furthermore, the phospholipid bilayer should be regarded as a fluid mosaic [235].

Lipid rafts are specialized microdomains in eukaryotic cell membranes, enriched in sphingolipids and cholesterol, with a specific composition of phospholipids, including phosphoinositides, that can influence membrane order and permeability [236,237]. Additionally, lipid rafts create local spatial and electrical potential differences compared to surrounding membrane regions, promoting receptor clustering and anchoring of signaling molecules. From a cellular signaling perspective, phosphoinositides act as first intracellular messengers, initiating downstream signaling cascades at the plasma membrane and on endosomal membranes after receptor internalization [238]. Moreover, the triggered cascades are regulating this cycle in feedback loops

[e.g., via RHO-GTPases (Ras homologous) and cell division cycle 42 (Cdc42 - part of the RHO family)] [239,240].

Fallahi-Sichani and Linderman showed that lipid rafts as membrane microdomains influence the localization of receptors like GPCRs [241]. With rapid dimerization and monomerization, frequent partner changes lead to the formation of oligomeric receptor clusters. In addition, the effect of ligands varies broadly: “while some GPCRs are stimulated to dimerize by ligands, others are inhibited - indicating a differential, ligand-dependent receptor organization.” [241]

5.2. *The Role of Lipid Rafts in LNP Uptake into Cells*

Building on the role of lipid rafts in receptor localization and oligomeric clustering described by Fallahi-Sichani and Linderman [241], it has been suggested that these membrane microdomains also play a critical role in mediating interactions with exogenous particles. Wang et al. highlight that the ordered structure of lipid rafts can facilitate interactions between LNPs and the cellular membrane, thereby enhancing intracellular uptake through endocytosis [242]. Furthermore, the specific organization of these domains may mimic natural raft structures, improving recognition and internalization processes regulated by lipid rafts. Since lipid rafts organize receptor clusters and serve as platforms for regulated signaling and endocytosis, phosphatidylinositides emerge as key intracellular messengers and spatial organizers within these microdomains. Their composition and dynamic turnover help coordinate receptor localization, membrane trafficking, and downstream signaling events, highlighting their central role in understanding how LNPs may influence cellular homeostasis.

5.3. *Signaling Through Phosphorylation States of Phosphatidylinositols*

Phosphatidylinositol phosphates (PIPs) are derivatives of PIs, which orient themselves to the cytosolic side of the membrane through the phosphorylatable inositol head groups [243]. PIs are amphiphilic and electrically neutral, and they are integral components of the cell membrane. They make up about 1%–5% (depending on membrane type) of the entire lipid mosaic [244]. In contrast, their phosphorylated derivatives (PIPs) are electrically negatively charged and functionally active both in the cell membrane and in the cytosol, where they are localized membrane-bound in organelles such as early endosomes. Despite their low concentration in the phospholipid membrane mosaic, their role in phagocytosis, endocytosis, receptor-mediated endocytosis, and macro- and micropinocytosis is essential (see **Figure 2**).




Figure 2. The PtdIns cycle and the organelle trafficking. 1. Biological roles of PtdIns-Cycle KINASES and their derivatives in membranes [see Supplementary Table 1]. a. early endosome, PI4P; PI3P, generated by class III PI3K: Defines endosome identity, recruits effectors such as ESCRT-0 and SNX proteins for cargo sorting; b. recycling endosome, PI(4,5)P₂; PI4P; PI3P: resorting and rebalancing of PPIs/PIPs-balance. c. late endosome, PI3P; increasingly PI(3,5)P₂ via PIKfyve: Regulates cargo sorting and multivesicular body (MVB) formation for exosomes or lysosomal fusion; d. Endolysosomal transition; PI(3,5)P₂; partially PI3P: Supports lysosomal functions (e.g., ion channels, V-ATPase) and reformation. e. Lysosome; PI(3,5)P₂ via PIKfyve; various PIPs depending on the state: Regulates breakdown of intracellular components and autophagic lysosome reformation (ALR); f. Autolysosome PI3P (from autophagosomes); PI(3,5)P₂ (from lysosomes); PI(4,5)P₂ during ALR; PI4P PI(3,4)P₂: regulates fusion and ALR; PI(4,5)P₂ recruits clathrin/AP-2 for tubulation. 2. and 3. Exocytosis [directly via MVB (see c.) or trans golgi]; PI4P; PI(4,5)P₂ (also in the Golgi active): extracellular trafficking; 4. Autophagosome PI3P, generated by class III PI3K at the ER: Recruits WIP12 for phagophore expansion and LC3 lipidation. Created in BioRender. Seger, F. (2025) <https://BioRender.com/s8tc5vs>.

Posor et al. describe the PI cycle (Supplementary Table S1 and Figure S2) as a tightly regulated network of dynamic transitions between phosphorylation states, such as PI(4,5)P₂ and PI(3,4,5)P₃ [243]. This cycle regulates the processing and degradation of endosomes formed from the plasma membrane. During endosome formation, PIPs mark endosomes by binding to their membranes, a process initiated by membrane-membrane contact, acting as key modulators of downstream signaling pathways, including GTPases [245]. The phosphorylation of PIPs is controlled by kinases such as phosphatidylinositol-3-kinase (PI3K) and phosphatases such as the inositol polyphosphate 5-phosphatases (INPPs) [246,249] and phosphatase and tensin homolog (PTEN), as well as downstream signals, most notably, Akt. PIPs undergo a cyclic transition, for example from PI(3,4,5)P₃ to PI(4,5)P₂. These dynamics govern organelle maturation and transitions, such as the endosomal-lysosomal pathway. Moreover, PIPs play a critical role in balancing phospholipid recycling and degradation, essential for membrane restructuring and integrity (see Figure 2). [243,246] Furthermore, the PtdIns cycle also controls RAB GTPases, integrating phosphoinositide signaling with the mechanical regulation of plasma membrane dynamics and organelle membrane trafficking [247,248].

5.4. Oxysterol-Binding Proteins (OSBs) and a Role for Cholesterol

Emerging evidence suggests that oxysterol-binding protein (OSBP)-related proteins (OSB proteins; also known as oxysterol homology (OSH) proteins) contribute to membrane organization and reorganization [250,251]. Since the PtdIns cycle is a key regulator of membrane dynamics, this points to additional layers of regulation that are not yet fully understood. It further raises the possibility of extensive crosstalk between PtdIns metabolism and OSH proteins in coordinating membrane reorganization. OSH proteins also bind to oxidized cholesterol. This raises the question of what role cholesterol in lipid nanoparticles could play in membrane disturbances, particularly since the particles induce an inflammatory response [252].

Given that PIPs mark endosomal membranes and tightly regulate organelle maturation and trafficking, any disruption of their dynamic phosphorylation-dephosphorylation cycles can compromise membrane integrity. Lipid nanoparticles (LNPs), upon endocytic uptake, introduce high local concentrations of cationic or ionizable lipids into the endosomal membrane. These lipids interact with the negatively charged PIPs and the surrounding phospholipid matrix, destabilizing the tightly regulated membrane environment described above. Consequently, this can lead to endosomal and lysosomal membrane holes or pores, facilitating the cytosolic release of encapsulated cargo such as modRNA, while bypassing the canonical degradation pathways that are normally orchestrated by the PI cycle [158,253].

In Section 2, we also discussed that only 3% - maximum 15% of cargo-containing LNPs (depending on the formulation and cell type) actually reach the phase of endosomal/lysosomal escape [25]. Furthermore, Paramasivam et al. showed that the efficiency of endosomal escape does not correlate with overall uptake, indicating that the fraction of LNPs reaching endosomes is largely independent of how efficiently they later escape into the cytosol [82]. In other terms, that means that it is not known how many LNPs are taken up and how many stay in the endosomal/lysosomal/autophagosome transition.

Recent spatiotemporal analyses using sensitive LNP labeling platforms further support this notion, showing that continuous endocytosis and endolysosomal trafficking are required to maintain pools of releasable compartments, thereby mechanistically explaining why only a fraction of LNPs achieve cytosolic release while the remainder remains in lysosomes [254]. This partial efficiency highlights the unresolved question of how the remaining LNPs, which do not induce endosomal rupture and are trafficked to lysosomes, are subsequently degraded or recycled within the cell, and whether their presence might disturb these important processes.

Lipid nanoparticles (LNPs), upon endocytic uptake, introduce high local concentrations of cationic or ionizable lipids into the endosomal membrane, a phenomenon that has been highlighted as a major determinant of both efficacy and toxicity of LNP formulations [91]. Moreover, Jørgensen et al. suggest that even the biodegraded blocks of the protonated tertiary amines (ionizable lipids) like ALC-0315 and SM-102 remain bioactive. The authors note: "However, they are neither synthesized from endogenous or natural structures nor are they degraded into typical biocompatible building blocks" [91].

5.5. How Does 1,2-distearoyl-sn-glycero-3-Phosphocholine (DSPC) Affect the PI Cycle?

In the context of the recycling processes and membrane organization, another aspect that has received little attention is the phospholipid, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) [255,256], which is used as an auxiliary lipid in LNPs. DSPC (also known as 18:0/18:0) has two saturated stearic acid chains. While structurally similar to the phospholipids naturally found in cell membranes, DSPCs are more tightly packed, more rigid, and more thermally stable [257] than the typical 18:0/18:1 and 18:1/18:1 phospholipids found in eukaryotic membranes [234,258]. It has a high gel-liquid transition temperature (T_m approx. 55°C), which confers it with unusual rigidity [259]. It is a natural phospholipid, primarily found in human pulmonary surfactant [260].

This raises the question of how DSPC affects the PI-cycle, as it is known that PCs are recycled into various phospholipids, including PI. Phospholipase D, which converts PCs into phosphatidic acid (PA), plays an essential role in this process [261–263]. PA is converted into CDP-diacylglycerol

(CDP-DAG) by CDP-DAG synthase, a key step in channeling PA into the biosynthesis of PI and other phospholipids [264,265]. CDP-DAG subsequently serves as the immediate precursor for phosphatidylinositols, synthesized by PI synthase at the endoplasmic reticulum, forming the core PI scaffold [265,266].

To the best of our knowledge, it remains uncharacterized how DSPC is degraded and whether it can interfere with membrane physiology beyond the process of transfection through recycling. After 24 hours, most DSPC primarily accumulates in the liver, spleen, heart, kidney, and lung, indicating that these organs' plasma membranes take up the lipid [267]. This confirms DSPC's tissue delivery and retention. However, it is known that liposomes composed of phospholipids such as DSPC can strikingly alter membrane structure, as previously discussed in the review by Loney et al. [223]. The exact cellular mechanism *in vivo* remains poorly characterized. Studies indicate that DSPC-containing liposomes can undergo hydrolytic and oxidative degradation, producing phospholipid-derived products that may alter membrane structure and stability in unpredictable ways [268,269].

Although not yet demonstrated *in vivo*, it is conceivable that lipid nanoparticles may interfere with autophagic lysosome reformation (ALR) [270,271], a process essential for sustaining lysosomal homeostasis and autophagic flux [272,273]. Since ALR depends on phosphoinositide transitions [274] and clathrin-mediated membrane remodeling [275], the insertion of ionizable lipids into these organelles could compromise the delicate balance of lysosomal recycling. Such perturbations may not only disturb autophagic flux but could also contribute to organ-specific toxicities observed with LNPs [106].

5.6. A Role for Lipid Impurities

As we suggested in Section 2, LNPs act as bioactive particles with unpredictable biodistribution and transfection pathways (see also Gutschli & Seger [12] for mechanistical insight). It remains unclear under which membrane conditions their proposed mechanisms of action will occur. Furthermore, it is not known how lipid impurities may influence the processes of endosomal-lysosomal transition, autophagosome formation and the subsequent autophagosome-lysosome fusion leading to autolysosome formation.

One of the most likely occurring lipid impurities are covalent lipid adducts. Covalent RNA-lipid adducts, a class of degradation products first identified by Packer et al. [93] are formed during manufacturing and storage. *In vitro* studies have demonstrated that oxidative and hydrolytic transformations of tertiary amine-containing lipids (e.g., SM-102, ALC-0315, DLin-MC3-DMA) can generate electrophilic fatty aldehyde species and secondary amines. These aldehydes are reactive towards the nucleobases to form stable covalent adducts, rendering the modRNA untranslatable [99]. Adducts are chemically stable and can persist unless removed or prevented. However, if adducted modRNA, present in the vaccine, is taken up by the cell, it may be perceived as abnormal or viral-like by cellular sensors [96]. RNA-adducts may trigger inflammatory signals or interferon responses, contributing to systemic immune dysregulation, ribosomal stalling, and collision with trailing ribosomes, as well as inflammatory responses [16], especially in vulnerable individuals [276,277]. Research on secondary amines and reactive aldehydes (e.g., 4-HNE, a product of lipid peroxidation) suggests that they can be cytotoxic. It may affect protein folding or function, leading to the formation of neoantigens that can provoke undesired immune responses [97], and they may contribute to oxidative stress and lysosomal dysfunction [98]. However, direct *in vivo* evidence of new adduct formation after LNP uptake has not been confirmed. It remains unclear how such covalent lipid adducts affect organelle function and trafficking (e.g., the transition-from endosome to lysosome), and consequently, the PI cycle.

5.7. Small Perturbations Can Lead to Major Shifts in PIP Signaling

Recent work by Fung et al. on the nonlinear dynamics of phosphoinositide metabolism demonstrates that PIP interconversion is governed by both feedback and feedforward circuits, excitable and oscillatory regimes, and kinetic thresholds, such that small perturbations in membrane

composition, enzyme activity, or lipid transport can produce disproportionately large and sometimes paradoxical shifts in PIP balance [278]. This nonlinearity implies that local perturbations introduced by LNPs (ionizable lipids, DSPC, pH changes) can push the system across dynamical, non-linear thresholds, radically altering endosomal identity, trafficking and release outcomes [279]. Simple formulation 'optimization' may therefore be insufficient to guarantee predictable delivery across all cell types and physiological states.

This perspective underscores a paradigm shift, as the effects of LNP-induced perturbations are not simply additive but can surpass critical thresholds that traditional toxicology approaches may fail to detect because they are insufficient for modelling such complex, self-assembling, bioactive nanosystem-like lipid nanoparticles. In summary, the findings discussed above suggest that such continuous disturbances can accumulate over years before manifesting in clinically significant pathological conditions. Thus, any concept of lipid nanoparticles that does not consider the complete intracellular processing governed by phosphoinositides and signaling cascades such as MAPKs remains incomplete. The outcomes of Fung *et al.*'s results [278] are consistent with observations of non-linear signal transduction, which we will consider in more detail in the discussion regarding consequences and conclusions of our hypothesis. There is growing evidence that PIPs act as a central hub integrating cell signaling and mechanical regulation through feedback loops involving cytoskeletal dynamics and membrane remodeling [280,281].

6. Discussion

Current evidence indicates that mRNA-LNPs first enter the lymphatic system via immune cell uptake and drainage from the injection site, reaching peak local concentrations in draining lymph nodes and the spleen [24,35]. From there, a fraction enters the systemic circulation where possible remodeling processes and the formation of lipoprotein- and protein-corona particles modify their composition and tropism. These restructured vesicles can reach secondary sites, including the liver and endothelial cells, as visualized at single cell resolution by Luo *et al.* [34]. In addition, circulating and muscle resident immune cells undergo direct transfection, acting as vectors for further modRNA dispersal. The relative contributions of these different trajectories, static tissue transfection, circulating immune cell uptake and exosome-mediated transfer, potentially including neural tissues, remains poorly quantified [25].

There is an open question that results from the biodistribution studies which was inconclusive and not further addressed. As immune cells take up and may already be transfected by LNPs, they migrate via physiological homing to lymphatic tissues [282–284]. This effect is also observed for muscle resident dendritic cells (DCs) [282], while muscle resident macrophages interact with diverse other migrating cells [285]. Some LNPs remain at the injection site and are taken up by and/or locally transfect muscle residing immune cells, while other LNPs enter the circulation and may also transfect immune cells in circulation or resident cells in distant tissues [122]. These processes may therefore establish three interconnected inflammatory environments: local responses in the muscle, systemic interactions among circulating immune cells [36], and dynamic reactivation within lymphatic tissues, as both naïve and previously activated immune cells undergo homing and recirculation. It is not known how the suggested mechanism of disturbed membrane dynamics will affect the immune cell homing [286].

It remains unclear how many of these cells achieve productive endosomal escape and translation of the LNP cargo versus how many experience primarily signaling perturbations. This stochastic distribution (see also Section 2 for more details), together with the individualized protein corona acquired by each LNP, may generate context-dependent and heterogeneous immune responses and inflammatory conditions across tissues and in the systemic lymphoid network [287].

Another inadequately addressed concern is the signaling transduction network. As we have synthesized in this hypothesis-driven review, it is evident that LNPs induce nonlinear and poorly characterized changes that profoundly affect cell behavior, potentially leading to dysregulated

protein kinase signaling [288]. The most probable initial cascade starts at the level of membrane physiology. It is evident that membrane integrity plays a striking role in health and disease [289–291].

New findings in cell and systems biology, as suggested for example by Szischik *et al.* [292], indicate a paradigm shift with regard to terms such as “transient” and “moderate” gene expression [293–298]. Veres *et al.* further demonstrated that the repetition rate of exposure over time and cell aging has a decisive influence on cell behavior [299]. Increasing evidence also indicates that the MAPK/ERK pathway serves as a master regulatory node, acting as one of the major hubs in intracellular signaling cascades (**Figure 3**) [300,301]. In this context, we propose that MAPKs and the PtdIns cycle interact through feed forward and feedback mechanisms, while additional cascades such as RHO and mTORC are also integrated within this network. Parres-Gold *et al.* provide one of the most remarkable clues as to why cellular signaling networks cannot be linear, since many molecules in dimerization networks exhibit competitive behavior [302]. This network logic raises an essential question about how an intrinsically nonlinear technology such as LNPs may perturb this signaling logic and propagate systemic consequences through paracrine and endocrine communication pathways. Avraham and Yarden [303] showed that gene activation unfolds in temporally distinct waves, where delayed responses progressively stabilize cellular states [303]. Disruption of this timing can shift transient regulation toward persistent dysregulation which can lead to pathological conditions. As Fung *et al.* [278] suggest, this network logic, including oscillations and mixed-mode oscillations, starts already in the PtdIns Cycle, and, with that, in the membrane organization. PtdIns signaling plays a complex role in neuroexcitosis and dysregulated autophagy associated with neurodegenerative disease [304,305].

If our L-DMD hypothesis is correct, as supported by Houthaeve *et al.* [306], who discussed the consequences for the cytoskeleton when membrane changes occur, it can be assumed that intracellular processing will undergo changes that will lead to epigenetic as well as paracrine and endocrine communication changes, which could have unknown consequences over longer periods of time. Avraham and Yarden initially highlighted this pattern, revealing gene expression in three temporally delayed phases [303]. Extrapolating this observation from a single cell to systemic effects leads to an uncertain period during which unpredictable changes in signaling pathways may occur, potentially leading to further gene expression changes, especially considering the inherent nonlinearities.




Figure 3. Nonlinear signaling crosstalk network between the PI3K-AKT-mTOR and RAS-ERK pathways via the phosphatidylinositol (PtdIns) cycle. GPCR activation at the plasma membrane, showing the heterotrimeric G-protein subunits $G_{\alpha q}$, G_{β} , and G_{γ} , triggers PI3K-dependent conversion of PIP_2 to PIP_3 , thereby linking receptor signaling to downstream AKT/mTOR and RAS/ERK cascades that regulate cell growth, survival, and metabolic control. Crosstalk to the insulin receptor via RGS proteins is indicated. **Created in BioRender. Seger, F. (2025) <https://BioRender.com/v125hmc>.**

7. Conclusions

Based on our hypothesis and the evidence presented in this work, which together suggest a biologically active role of lipid nanoparticles beyond mere cargo delivery, we conclude that further targeted research is urgently needed to clarify the full range of their systemic and long-term effects. Human-relevant animal studies that closely mirror physiological conditions, quantifying biodistribution and immune responses, should be prioritized to establish a reliable understanding of safety and mechanisms. A systems toxicology framework should be used. We recommend a particular focus on lipidomics, transcriptomics, and proteomics, based on single-cell analyses and blood samples or comparable methods. For detailed recording of biodistribution, *in vivo* methods employing pig and primate models, due to their comparable metabolic properties, should be used, including long-term observations and multiple dosing or booster effects. Therefore, newer methods should be considered. Furthermore, more precise approaches, such as SPARKLE (see Introduction) and single-cell-based analyses, should be standardized to gain a better understanding of biodistribution and transfection events.

The possibility of delayed or persistent alterations in cellular homeostasis, metabolism, and/or signaling pathways requires future systematic investigation, as this remains insufficiently addressed

in current datasets. Before any further large-scale application of LNP-modRNA-technology is pursued, our hypothesis of L-DMD should be comprehensively tested and, where possible, falsified through independent experimental approaches. Moreover, such alterations could give rise to synergistic, antagonistic, or additive effects mediated by the modRNA itself, further complicating the interpretation of downstream signaling and systemic outcomes.

Clinical pharmacology studies assessing potential alterations in cytochrome P450 activity after LNP exposure are also essential. Controlled pharmacokinetic studies should measure shifts in clearance, area under the curve, and metabolic ratios for representative CYP substrates before and after LNP administration, along with hepatic and pro-inflammatory cytokine levels. This helps determine whether enzyme downregulation is temporary and cytokine-driven, or due to direct lipid-enzyme interactions.

Taken together, our hypothesis underscores the need for a cautious, evidence-based reassessment of lipid nanoparticle technologies and for long-term monitoring that fully captures their biological and clinical impact. To emphasize scientific integrity and prevent misinterpretation, it should be clearly stated that the proposed mechanism represents a working hypothesis, derived from converging molecular and experimental observations, which requires systematic validation and possible falsification through independent studies before any definitive conclusions about clinical relevance are drawn. Only through transparent, independently verified research integrating molecular mechanisms with longterm physiological observations can the safety profile of LNP-modRNA technologies be accurately defined.

Author Contributions: All authors contributed to the conceptualization, the first draft of the manuscript, and to multiple rounds of edits.

Acknowledgements: All figures were created by F. Seger using BioRender, under BioRender's Terms of Service and Academic License.

Use of Generative AI: In preparing this work, the authors used ChatGPT to improve the comprehensibility of certain sentences. The authors reviewed and edited the content as necessary and take full responsibility for the published material.

Conflicts of Interest: The authors declare that they have no competing interests.

List of Abbreviations

4HNE: 4-Hydroxynonenal

AKT: Protein Kinase B

ALC-0315: ionizable lipid,[(4-hydroxybutyl)azanediyl]di(hexane-6,1-diyl) bis(2-hexyldecanoate)

ALR: Autophagic Lysosome Reformation

AMPK: AMP-Activated Protein Kinase

APC: Antigen-Presenting Cell

AhR: Aryl Hydrocarbon Receptor

ApoE: Apolipoprotein E

BUB1: Budding Uninhibited by Benzimidazoles 1

C57BL/6: C57 black 6: a common inbred mouse strain

CARPA: Complement Activation-Related Pseudoallergy

CCL2/3/4/7: Chemokine Ligands

CDC25A: Cell Division Cycle 25A

CDP-DAG: Cytidine Diphosphate Diacylglycerol

CRP: C-Reactive Protein

CSF2RB: Colony Stimulating Factor 2 Receptor Beta

CYP1A2, CYP2C9, CYP2C19, CYP3A4: Cytochrome Isoenzymes

CYP: Cytochrome P450

DC: Dendritic Cell

DEPs: Differentially Expressed Proteins
DLin-MC3-DMA: ionizable lipid, (6Z,9Z,28Z,31Z)-Heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate
DSPC: 1,2-Distearoyl-sn-glycero-3-Phosphocholine
E2F/E2F1/E2F8: E2F Transcription Factor Family
EMA: European Medicines Agency
ER: Endoplasmic Reticulum
ERK: Extracellular Signal-Regulated Kinase
ESCRT: Endosomal Sorting Complex Required for Transport
FDR: False Discovery Rate
GM-CSF: Granulocyte-Macrophage Colony-Stimulating Factor
GPCR: G-Protein Coupled Receptor
GSEA: Gene Set Enrichment Analysis
HDL: High-Density Lipoprotein
IFN- γ : Interferon- γ
IL-1 β , IL-2, IL-6, IL-17: Interleukins
IRF: Interferon Regulatory Factor
IgE, IgM, IgG: Immunoglobulin Isotypes
JAK-STAT: Janus Kinase - Signal Transducer and Activator of Transcription
KEGG: Kyoto Encyclopedia of Genes and Genomes
KRAS: Kirsten Rat Sarcoma Oncogene
L-DMD: Lipid-Nanoparticle-Driven Membrane Dysfunction
LC3: Microtubule-Associated Protein 1A/1B-Light Chain 3
LDL-R: Low-Density Lipoprotein Receptor
LDL: Low-Density Lipoprotein
LNP: Lipid Nanoparticle
MAPK/ERK: The RAS-RAF-MEK-ERK Pathway
MAPK: Mitogen-Activated Protein Kinase
MC3: ionizable lipid also known as D-Lin-MC3-DMA
MDDC: Monocyte-Derived Dendritic Cell
MSigDB: Molecular Signatures Database
MVB: Multivesicular Body
MyD88: Myeloid Differentiation Primary Response 88
NES: Normalized Enrichment Score
NF- κ B: Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
NIK/RELA/RELB: NF- κ B Pathway Subunits
NLRP3: NOD-Like Receptor Family Pyrin Domain Containing 3
NOD: Nucleotide-Binding Oligomerization Domain
OSBP/OSH: Oxysterol-Binding Protein / Yeast Ortholog
PA: Phosphatidic Acid
PBMC: Peripheral Blood Mononuclear Cell
PBS: Phosphate-Buffered Saline
PC: Phosphatidylcholine
PEG: Polyethylene Glycol
PEGylated: Covalently Modified with Polyethylene Glycol
PET-CT: Positron Emission Tomography-Computed Tomography
PI3K: Phosphatidylinositol-3-Kinase
PI3P, PI4P, PI (4,5) P2, PI (3,4,5) P3: Phosphorylated PI Species
PIP: Phosphoinositide
PPAR: Peroxisome Proliferator-Activated Receptor
PTEN: Phosphatase and Tensin Homolog

PtdIns/PI: Phosphatidylinositol
 RE: Recycling Endosome
 RES: Reticuloendothelial System
 RIG-I: Retinoic Acid-Inducible Gene I
 ROS: Reactive Oxygen Species
 RRM2: Ribonucleotide Reductase Regulatory Subunit M2
 SM-102: ionizable lipid:1-Octylnonyl 8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy) hexyl]amino]octanoate
 SPARKLE: Strategic Peptide Anchored Retained Kept after Lipid Elimination
 STAT3/STAT5: Signal Transducer and Activator of Transcription 3 / 5
 TBK1: Tank-Binding Kinase 1
 TCA: Tricarboxylic Acid Cycle
 TGF- β : Transforming Growth Factor β
 TLR2/3/4/7/8/9: Specific Toll-Like Receptor Types
 TLR: Toll-Like Receptor
 TNF- α : Tumor Necrosis Factor Alpha
 TRIF: TLR4 Signaling Adaptors
 Tm: Transition Temperature
 V-ATPase: Vacuolar ATPase
 WIPI2: WD Repeat Domain Phosphoinositide-Interacting Protein 2
 WT: Wild Type
 mRNA: Messenger Ribonucleic Acid
 mTOR/mTORC1/mTORC2: Mechanistic Target of Rapamycin (Complex 1 / 2)
 modRNA: Modified Messenger RNA
 p53: Tumour Suppressor Protein p53
 qPCR: Quantitative Polymerase Chain Reaction
 siRNA: Small Interfering RNA
 ζ : Zeta Potential (Surface Charge)

References

1. Khurana A, Allawadhi P, Khurana I, Allwadhi S, Weiskirchen R, Banothu AK, Chhabra D, Joshi K, Bharani KK. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. *Nano Today*. 2021 Jun;38:101142. doi: 10.1016/j.nantod.2021.101142.
2. Hald Albertsen C, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. *Adv Drug Deliv Rev* 2022; 188: 114416. doi: 10.1016/j.addr.2022.114416.
3. Swetha K, Kotla NG, Tunki L, Jayaraj A, Bhargava SK, Hu H, Bonam SR, Kurapati R. Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines. *Vaccines (Basel)*. 2023 Mar 14;11(3):658. doi: 10.3390/vaccines11030658.
4. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. *Adv Drug Deliv Rev*. 2016 Apr 1;99(Pt A):28-51. doi: 10.1016/j.addr.2015.09.012.
5. Ju Y, Carreo JM, Simon V, Dawson K, Krammer F, Kent SJ. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. *Nat Rev Immunol*. 2023 Mar;23(3):135-136. doi: 10.1038/s41577-022-00825-x.
6. Zhou ZH, Stone CA Jr, Jakubovic B, Phillips EJ, Sussman G, Park J, Hoang U, Kirshner SL, Levin R, Kozlowski S. Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. *J Allergy Clin Immunol Pract*. 2021 Apr;9(4):1731-1733.e3. doi: 10.1016/j.jaip.2020.11.011.
7. Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. *Adv Drug Deliv Rev*. 2020;154-155:163-175. doi: 10.1016/j.addr.2020.07.024.
8. Khalid MB, Frischmeyer-Guerrerio PA. The conundrum of COVID-19 mRNA vaccine-induced anaphylaxis. *J Allergy Clin Immunol Glob*. 2023 Feb;2(1):1-13. doi: 10.1016/j.jacig.2022.10.003.

9. Zelkoski AE, Lu Z, Sukumar G, Dalgard C, Said H, Alameh MG, Mitre E, Malloy AMW. Ionizable lipid nanoparticles of mRNA vaccines elicit NF- κ B and IRF responses through toll-like receptor 4. *NPJ Vaccines*. 2025 Apr 17;10(1):73. doi: 10.1038/s41541-025-01124-x.
10. Lee Y, Jeong M, Park J, Jung H, Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. *Exp Mol Med*. 2023 Oct;55(10):2085-2096. doi: 10.1038/s12276-023-01086-x.
11. Kimura S, Okada K, Matsubara N, Lyu F, Tsutsumi S, Kimura Y, Hashiya F, Inagaki M, Abe N, Abe H. In vivo demonstration of enhanced mRNA delivery by cyclic disulfide-containing lipid nanoparticles for facilitating endosomal escape. *RSC Med Chem*. 2025 Jun 27;16(9):4122-4137. doi: 10.1039/d5md00084j.
12. Gutsch LM, Seger F. Complexity, unpredictability and safety challenges of lipid nanoparticles. Zenodo preprint. Oct 13, 2025. doi: 10.5281/zenodo.17342543.
13. Lavington S, Watts A. Lipid nanoparticle technologies for the study of G protein-coupled receptors in lipid environments. *Biophys Rev*. 2020 Nov 19;12(6):1287-302. doi: 10.1007/s12551-020-00775-5.
14. Sakurai Y, Watanabe H, Nishio K, Hashimoto K, Harada A, Gomi M, Suzuki M, Oyama R, Handa T, Sato R, Takeuchi H, Taira R, Tezuka K, Tange K, Nakai Y, Akita H, Uchida Y. pH-Responsive lipid nanoparticles achieve efficient mRNA transfection in brain capillary endothelial cells. *Pharmaceutics*. 2022 Jul 27;14(8):1560. doi: 10.3390/pharmaceutics14081560.
15. Boros LG, Kyriakopoulos AM, Brogna C, Piscopo M, McCullough PA, Seneff S. Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. *Pharmacol Res Perspect*. 2024 Jun;12(3):e1218. doi: 10.1002/prp2.1218.
16. Cordes J, Zhao S, Engel CM, Stingle J. Cellular responses to RNA damage. *Cell*. 2025 Feb 20;188(4):885-900. doi: 10.1016/j.cell.2025.01.005.
17. Kaludercic N, Deshwal S, Di Lisa F. Reactive oxygen species and redox compartmentalization. *Front Physiol*. 2014 Aug 12;5:285. doi: 10.3389/fphys.2014.00285.
18. Kim KQ, Burgute BD, Tzeng SC, Jing C, Jungers C, Zhang J, Yan LL, Vierstra RD, Djuranovic S, Evans BS, Zaher HS. N1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products. *Cell Rep*. 2022 Aug 30;40(9):111300. doi: 10.1016/j.celrep.2022.111300.
19. Röltgen K, Nielsen SCA, Silva O, Younes SF, Zaslavsky M, Costales C, Yang F, Wirz OF, Solis D, Hoh RA, Wang A, Arunachalam PS, Colburg D, Zhao S, Haraguchi E, Lee AS, Shah MM, Manohar M, Chang I, Gao F, Mallajosyula V, Li C, Liu J, Shoura MJ, Sindher SB, Parsons E, Dashdorj NJ, Dashdorj ND, Monroe R, Serrano GE, Beach TG, Chinthrajah RS, Charville GW, Wilbur JL, Wohlstadter JN, Davis MM, Pulendran B, Troxell ML, Sigal GB, Natkunam Y, Pinsky BA, Nadeau KC, Boyd SD. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. *Cell*. 2022 Mar 17;185(6):1025-1040.e14. doi: 10.1016/j.cell.2022.01.018.
20. Kim W, Ly NK, He Y, Li Y, Yuan Z, Yeo Y. Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery. *Adv Drug Deliv Rev*. 2023 Jan;192:114635. doi: 10.1016/j.addr.2022.114635.
21. Suzuki Y, Ishihara H. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs. *Drug Metab Pharmacokinet*. 2021 Dec;41:100424. doi: 10.1016/j.dmpk.2021.100424.
22. Buckley M, Araújo M, Maiorino L, Pires IS, Kim BJ, Michaels KK, Dye J, Qureshi K, Zhang YJ, Mak H, Steichen JM, Schief WR, Villinger F, Irvine DJ. Visualizing lipid nanoparticle trafficking for mRNA vaccine delivery in non-human primates. *Mol Ther*. 2025 Mar 5;33(3):1105-1117. doi: 10.1016/j.ymthe.2025.01.008.
23. Sasaki K, Sato Y, Okuda K, Iwakawa K, Harashima H. mRNA-loaded lipid nanoparticles targeting dendritic cells for cancer immunotherapy. *Pharmaceutics*. 2022 Jul 28;14(8):1572. doi: 10.3390/pharmaceutics14081572.
24. Hassett KJ, Rajlic IL, Bahl K, White R, Cowens K, Jacquinet E, Burke KE. mRNA vaccine trafficking and resulting protein expression after intramuscular administration. *Mol Ther Nucleic Acids*. 2023 Nov 24;35(1):102083. doi: 10.1016/j.omtn.2023.102083.
25. Maugeri M, Nawaz M, Papadimitriou A, Angerfors A, Camponeschi A, Na M, Hölttä M, Skantze P, Johansson S, Sundqvist M, Lindquist J, Kjellman T, Mrtensson I-L, Jin T, Sunnerhagen P, Ostman S,

- Lindfors L, Valadi H. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. *Nat Commun* 2019; 10: 4333. <https://doi.org/10.1038/s41467-019-12275-6>
26. Inam W, Bhadane R, Akpolat RN, Taiseer RA, Filippov SK, Salo-Ahen OMH, Rosenholm JM, Zhang H. Interactions between polymeric nanoparticles and different buffers as investigated by zeta potential measurements and molecular dynamics simulations. *View* 2022; 3(4): 20210009. <https://doi.org/10.1002/VIW.20210009>.
 27. Simak J, De Paoli S. The effects of nanomaterials on blood coagulation in hemostasis and thrombosis. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2017 Sep;9(5). doi: 10.1002/wnan.1448.
 28. Brooks DE, Seaman GVF. The effect of neutral polymers on the electrokinetic potential of cells and other charged particles. I. Models for the zeta potential increase. *J Colloid Interf Sci*. 1973; 43 (3):670-686.
 29. Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system. Part II: safety concerns. *Nanomedicine (Lond)*. 2013 Jun;8(6):969-81. doi: 10.2217/nnm.13.49.
 30. Omo-Lamai S, Zamora ME, Patel MN, Wu J, Nong J, Wang Z, Peshkova A, Majumder A, Melamed JR, Chase LS, Essien EO, Weissman D, Muzykantov VR, Marcos-Contreras OA, Myerson JW, Brenner JS. Physicochemical targeting of lipid nanoparticles to the lungs induces clotting: Mechanisms and solutions. *Adv Mater*. 2024 Jun;36(26):e2312026. doi: 10.1002/adma.202312026.
 31. Bekal S, Husari G, Okura M, Huang CA, Bukari MS. Thrombosis development after mRNA COVID-19 vaccine administration: A Case Series. *Cureus*. 2023 Jul 4;15(7):e41371. doi: 10.7759/cureus.41371.
 32. Kent SJ, Li S, Amarasena TH, Reynaldi A, Lee WS, Leeming MG, O'Connor DH, Nguyen J, Kent HE, Caruso F, Juno JA, Wheatley AK, Davenport MP, Ju Y. Blood distribution of SARS-CoV-2 lipid nanoparticle mRNA vaccine in humans. *ACS Nano*. 2024 Oct 1;18(39):27077-27089. doi: 10.1021/acsnano.4c11652.
 33. Ren Y, Lin L, Abdallah M, Zhu X, Liu H, Fabb SA, Payne TJ, Pouton CW, Johnston APR, Trevaskis NL. Impact of ionizable lipid type on the pharmacokinetics and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection. *J Control Release*. 2025 Aug 10;384:113945. doi: 10.1016/j.jconrel.2025.113945.
 34. Luo J, Molbay M, Chen Y, Horvath I, Kadletz K, Kick B, Zhao S, Al-Maskari R, Singh I, Ali M, Bhatia HS, Minde DP, Negwer M, Hoeher L, Calandra GM, Groschup B, Su J, Kimna C, Rong Z, Galensowske N, Todorov MI, Jeridi D, Ohn TL, Roth S, Simats A, Singh V, Khalin I, Pan C, Arús BA, Bruns OT, Zeidler R, Liesz A, Protzer U, Plesnila N, Ussar S, Hellal F, Paetzold J, Elsner M, Dietz H, Erturk A. Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning. *Nat Biotechnol*. 2025 Jan 14. doi: 10.1038/s41587-024-02528-1. Epub ahead of print.
 35. Di J, Du Z, Wu K, Jin S, Wang X, Li T, Xu Y. Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size. *Pharm Res*. 2022 Jan;39(1):105-114. doi: 10.1007/s11095-022-03166-5.
 36. Dey AK, Nougarede A, Clément F, Fournier C, Jouvin-Marche E, Escudé M, Jary D, Navarro FP, Marche PN. Tuning the immunostimulation properties of cationic lipid nanocarriers for nucleic acid delivery. *Front Immunol*. 2021 Aug 23;12:722411. doi: 10.3389/fimmu.2021.722411.
 37. Zhang W, Liu R, Chen Y, Wang M, Du J. Crosstalk between oxidative stress and exosomes. *Oxid Med Cell Longev*. 2022 Aug 30;2022:3553617. doi: 10.1155/2022/3553617.
 38. Wei C, Zhu Y, Lu X, Goodier KD, Yu D, Liu X, Choy J, Calderón AT, Ma J, Su Y, Lin J, Li S, Schneck JP, Murphy SC, Mao H-Q. Systemic trafficking of mRNA lipid nanoparticle vaccine following intramuscular injection generates potent tissue-specific T cell response. *bioRxiv Preprint*. April 24, 2025. doi: 10.1101/2025.04.21.649878.
 39. Balcorta HV, Mata Corral MY, Gallegos A, Chavez J, Perez J, Balivada S, Natividad-Diaz SL, Poon W. Development of chemical tags for universal lipid nanoparticle visualization and tracking in 2D and 3D imaging. *Nano Lett*. 2025 May 14;25(19):7682-7689. doi: 10.1021/acs.nanolett.5c00311.
 40. Yamamoto K, Mashiba T, Takano K, Suzuki T, Kami M, Takita M, Kusumi E, Mizuno Y, Hamaki T. A case of exacerbation of subclinical hyperthyroidism after first administration of BNT162b2 mRNA COVID-19 vaccine. *Vaccines (Basel)*. 2021 Sep 29;9(10):1108. doi: 10.3390/vaccines9101108.
 41. Hummel A, Oniszczuk J, Kervella D, Charbit M, Guerrot D, Testa A, Philipponnet C, Chauvet C, Guincestre T, Brochard K, Benezech A, Figueres L, Belenfant X, Guarnieri A, Demoulin N, Benetti E, Miglinas M,

- Dessaix K, Morelle J, Angeletti A, Sellier-Leclerc AL, Ranchin B, Goussard G, Hudier L, Bacchetta J, Servais A, Audard V. Idiopathic nephrotic syndrome relapse following COVID-19 vaccination: a series of 25 cases. *Clin Kidney J.* 2022 May 6;15(8):1574-1582. doi: 10.1093/ckj/sfac134.
42. Malayala SV, Papudesi BN, Sharma R, Vusqa UT, Raza A. A case of idiopathic thrombocytopenic purpura after booster dose of BNT162b2 (Pfizer-Biontech) COVID-19 vaccine. *Cureus.* 2021 Oct 23;13(10):e18985. doi: 10.7759/cureus.18985.
 43. Shumnalieva R, Ravichandran N, Hannah J, Javaid M, Darooka N, Roy D, Gonzalez DE, Velikova T, Milchert M, Kuwana M, Joshi M, Gracia-Ramos AE, Boyd P, Yaadav P, Cheng K, Kobert L, Cavagna L, Sen P, Day J, Makol A, Gutiérrez CET, Caballero-Urbe CV, Saha S, Parodis I, Dey D, Nikiphorou E, Distler O, Kadam E, Tan AL, Shinjo SK, Ziade N, Knitza J, Chinoy H, Aggarwal R, Agarwal V, Gupta L; COVAD Study Group. Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD group. *Int J Rheum Dis.* 2024 May;27(5):e15178. doi: 10.1111/1756-185X.15178.
 44. Broachwala M, Banks DW, Jevotovsky DS, Oehlermarx W, Durbhakula S. Burning mouth syndrome following Covid vaccination: A case report. *Clin Case Rep.* 2025 Apr 29;13(5):e70329. doi: 10.1002/ccr3.70329.
 45. Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, Doshi P. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. *Vaccine.* 2022 Sep 22;40(40):5798-5805. doi: 10.1016/j.vaccine.2022.08.036.
 46. Faksova K, Walsh D, Jiang Y, Griffin J, Phillips A, Gentile A, Kwong JC, Macartney K, Naus M, Grange Z, Escolano S, Sepulveda G, Shetty A, Pillsbury A, Sullivan C, Naveed Z, Janjua NZ, Giglio N, Perälä J, Nasreen S, Gidding H, Hovi P, Vo T, Cui F, Deng L, Cullen L, Artama M, Lu H, Clothier HJ, Batty K, Paynter J, Petousis-Harris H, BATTERY J, Black S, Hviid A. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. *Vaccine.* 2024 Apr 2;42(9):2200-2211. doi: 10.1016/j.vaccine.2024.01.100.
 47. Kim HJ, Kim MH, Choi MG, Chun EM. 1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea. *Biomark Res.* 2025 Sep 26;13(1):114. doi: 10.1186/s40364-025-00831-w.
 48. Abbasi R, Shineh G, Mobaraki M, Doughty S, Tayebi L. Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review. *Journal of Nanoparticle Research* 2023; 25(3): 43. doi: 10.1007/s11051-023-05690-w.
 49. Yuan Z, Yan R, Fu Z, Wu T, Ren C. Impact of physicochemical properties on biological effects of lipid nanoparticles: Are they completely safe. *Sci Total Environ.* 2024 Jun 1;927:172240. doi: 10.1016/j.scitotenv.2024.172240.
 50. Szebeni J, Kiss B, Bozó T, Turjeman K, Levi-Kalisman Y, Barenholz Y, Kellermayer M. Insights into the structure of Comirnaty COVID-19 vaccine: A theory on soft, partially bilayer-covered nanoparticles with hydrogen bond-stabilized mRNA-lipid complexes. *ACS Nano.* 2023 Jul 25;17(14):13147-13157. doi: 10.1021/acsnano.2c11904.
 51. Brader ML, Williams SJ, Banks JM, Hui WH, Zhou ZH, Jin L. Encapsulation state of messenger RNA inside lipid nanoparticles. *Biophys J.* 2021 Jul 20;120(14):2766-2770. doi: 10.1016/j.bpj.2021.03.012.
 52. Münter R, Larsen JB, Andresen TL. The vast majority of nucleic acid-loaded lipid nanoparticles contain cargo. *J Colloid Interface Sci.* 2024 Nov 15;674:139-144. doi: 10.1016/j.jcis.2024.06.158.
 53. Li S, Hu Y, Li A, Lin J, Hsieh K, Schneiderman Z, Zhang P, Zhu Y, Qiu C, Kokkoli E, Wang TH, Mao HQ. Payload distribution and capacity of mRNA lipid nanoparticles. *Nat Commun.* 2022 Sep 23;13(1):5561. doi: 10.1038/s41467-022-33157-4.
 54. Chen X, Ye Y, Li M, Zuo T, Xie Z, Ke Y, Cheng H, Hong L, Liu Z. Structural characterization of mRNA lipid nanoparticles (LNPs) in the presence of mRNA-free LNPs. *J Control Release.* 2025 Oct 10;386:114082. doi: 10.1016/j.jconrel.2025.114082.
 55. Rampado R, Crotti S, Caliceti P, Pucciarelli S, Agostini M. Recent advances in understanding the protein corona of nanoparticles and in the formulation of “stealthy” nanomaterials. *Front Bioeng Biotechnol.* 2020 Apr 3;8:166. doi: 10.3389/fbioe.2020.00166.

56. Sun Y, Zhou Y, Rehman M, Wang YF, Guo S. Protein corona of nanoparticles: Isolation and analysis. *Chem Bio Eng.* 2024 Oct 3;1(9):757-772. doi: 10.1021/cbe.4c00105.
57. Voke E, Arral M, Squire HJ, Lin TJ, Coreas R, Lui A, Iavarone AT, Pinals RL, Whitehead KA, Landry M. Protein corona formed on lipid nanoparticles compromises delivery efficiency of mRNA cargo. *bioRxiv* [Preprint]. 2025 Jan 24:2025.01.20.633942. doi: 10.1101/2025.01.20.633942.
58. Sebastiani F, Yanez Arteta M, Lerche M, Porcar L, Lang C, Bragg RA, Elmore CS, Krishnamurthy VR, Russell RA, Darwish T, Pichler H, Waldie S, Moulin M, Haertlein M, Forsyth VT, Lindfors L, Cárdenas M. Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-containing lipid nanoparticles. *ACS Nano.* 2021 Apr 27;15(4):6709-6722. doi: 10.1021/acsnano.0c10064.
59. Liu K, Nilsson R, Lázaro-Ibáñez E, Duàn H, Miliotis T, Strimfors M, Lerche M, Salgado Ribeiro AR, Ulander J, Lindén D, Salvati A, Sabirsh A. Multiomics analysis of naturally efficacious lipid nanoparticle coronas reveals high-density lipoprotein is necessary for their function. *Nat Commun.* 2023 Jul 6;14(1):4007. doi: 10.1038/s41467-023-39768-9.
60. Hosseini-Kharat M, Bremmell KE, Prestidge CA. Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism. *Mol Ther Methods Clin Dev.* 2025 Feb 15;33(1):101436. doi: 10.1016/j.omtm.2025.101436.
61. Therapeutic Goods Administration. Nonclinical Evaluation Report BNT162b2 [mRNA] COVID-19 vaccine (COMIRNATY). Health, Ed.; Department of Health and Aged Care. <https://www.tga.gov.au/sites/default/files/foi-2389-06.pdf>, 2021; Vol. FOI 2389.
62. Neves AR, Queiroz JF, Costa Lima SA, Figueiredo F, Fernandes R, Reis S. Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: Relevance for oral drug delivery. *J Colloid Interface Sci.* 2016 Feb 1;463:258-65. doi: 10.1016/j.jcis.2015.10.057.
63. Haghghi E, Abolmaali SS, Dehshahri A, Mousavi Shaegh SA, Azarpira N, Tamaddon AM. Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach. *J Nanobiotechnology.* 2024 Nov 14;22(1):710. doi: 10.1186/s12951-024-02972-w.
64. Khare P, Edgecomb SX, Hamadani CM, Tanner EEL, S Manickam D. Lipid nanoparticle-mediated drug delivery to the brain. *Adv Drug Deliv Rev.* 2023 Jun;197:114861. doi: 10.1016/j.addr.2023.114861.
65. Chen J, Xu Y, Zhou M, Xu S, Varley AJ, Golubovic A, Lu RXZ, Wang KC, Yeganeh M, Vosoughi D, Li B. Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects. *Proc Natl Acad Sci U S A.* 2023 Dec 12;120(50):e2309472120. doi: 10.1073/pnas.2309472120.
66. Younis MA, Sato Y, Elewa YHA, Kon Y, Harashima H. Self-homing nanocarriers for mRNA delivery to the activated hepatic stellate cells in liver fibrosis. *J Control Release.* 2023 Jan;353:685-698. doi: 10.1016/j.jconrel.2022.12.020.
67. Naasani I. Establishing the pharmacokinetics of genetic vaccines is essential for maximising their safety and efficacy. *Clin Pharmacokinet.* 2022 Jul;61(7):921-927. doi: 10.1007/s40262-022-01149-8.
68. European Medical Assessment. 2020. <https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report-en.pdf>.
69. Akhter MH, Khalilullah H, Gupta M, Alfaleh MA, Alhakamy NA, Riadi Y, Md S. Impact of protein corona on the biological identity of nanomedicine: Understanding the fate of nanomaterials in the biological milieu. *Biomedicines.* 2021 Oct 19;9(10):1496. doi: 10.3390/biomedicines9101496.
70. Behzadi S, Serpooshan V, Tao W, Hamaly MA, Alkawareek MY, Dreaden EC, Brown D, Alkilany AM, Farokhzad OC, Mahmoudi M. Cellular uptake of nanoparticles: journey inside the cell. *Chem Soc Rev.* 2017 Jul 17;46(14):4218-4244. doi: 10.1039/c6cs00636a.
71. Chatterjee S, Kon E, Sharma P, Peer D. Endosomal escape: A bottleneck for LNP-mediated therapeutics. *Proc Natl Acad Sci U S A.* 2024 Mar 12;121(11):e2307800120. doi: 10.1073/pnas.2307800120.
72. Sengottayan S, Mikolajczyk A, Jagiełło K, Swirog M, Puzyn T. Core, coating, or corona? The importance of considering protein coronas in nano-QSPR modeling of zeta potential. *ACS Nano.* 2023 Feb 14;17(3):1989-1997. doi: 10.1021/acsnano.2c06977.
73. Fell VHK, Kramer T, Heindl A, Merkel OM. Prediction of the apparent pKa value of lipid nanoparticles by density functional theory. *ACS Mater Au.* 2025 Feb 27;5(3):451-457. doi: 10.1021/acsmaterialsau.4c00158.

74. Johansson JM, Du Rietz H, Hedlund H, Eriksson HC, Oude Blenke E, Pote A, Harun S, Nordenfelt P, Lindfors L, Wittrup A. Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol. *Nat Commun.* 2025 Jul 1;16(1):5354. doi: 10.1038/s41467-025-60959-z.
75. Ermilova I, Swenson J. Ionizable lipids penetrate phospholipid bilayers with high phase transition temperatures: perspectives from free energy calculations. *Chem Phys Lipids.* 2023 Jul;253:105294. doi: 10.1016/j.chemphyslip.2023.105294.
76. Er-Rafik M, Ferji K, Combet J, Sandre O, Lecommandoux S, Schmutz M, Le Meins J-F, Marques CM. Tear of lipid membranes by nanoparticles. *Soft Matter* 2022; 18(17): 3318-3322. doi: 10.1039/D2SM00179A.
77. Pilkington EH, Suys EJA, Trevaskis NL, Wheatley AK, Zukancic D, Algarni A, Al-Wassiti H, Davis TP, Pouton CW, Kent SJ, Truong NP. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. *Acta Biomater.* 2021 Sep 1;131:16-40. doi: 10.1016/j.actbio.2021.06.023.
78. Müller JA, Schäffler N, Kellerer T, Schwake G, Ligon TS, Rädler JO. Kinetics of RNA-LNP delivery and protein expression. *Eur J Pharm Biopharm.* 2024 Apr;197:114222. doi: 10.1016/j.ejpb.2024.114222.
79. Aliakbarinodehi N, Niederkofler S, Emilsson G, Parkkila P, Olsén E, Jing Y, Sjöberg M, Agnarsson B, Lindfors L, Höök F. Time-resolved inspection of ionizable lipid-facilitated lipid nanoparticle disintegration and cargo release at an early endosomal membrane mimic. *ACS Nano.* 2024 Aug 27;18(34):22989-23000. doi: 10.1021/acsnano.4c04519.
80. Schlich M, Palomba R, Costabile G, Mizrahy S, Pannuzzo M, Peer D, Decuzzi P. Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. *Bioeng Transl Med.* 2021 Mar 20;6(2):e10213. doi: 10.1002/btm2.10213.
81. Sabnis S, Kumarasinghe ES, Salerno T, Mihai C, Ketova T, Senn JJ, Lynn A, Bulychev A, McFadyen I, Chan J, Almarsson Ö, Stanton MG, Benenato KE. A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-human primates. *Mol Ther.* 2018 Jun 6;26(6):1509-1519. doi: 10.1016/j.ymthe.2018.03.010.
82. Paramasivam P, Franke C, Stöter M, Höijer A, Bartesaghi S, Sabirsh A, Lindfors L, Arteta MY, Dahlén A, Bak A, Andersson S, Kalaidzidis Y, Bickle M, Zerial M. Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale. *J Cell Biol.* 2022 Feb 7;221(2):e202110137. doi: 10.1083/jcb.202110137.
83. Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, Karagiannis E, Love K, Chen D, Zoncu R, Buganim Y, Schroeder A, Langer R, Anderson DG. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. *Nat Biotechnol.* 2013 Jul;31(7):653-8. doi: 10.1038/nbt.2614.
84. Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. *Nat Rev Drug Discov.* 2024 Apr;23(4):281-300. doi: 10.1038/s41573-023-00859-3.
85. Moghimi SM, Simberg D. Pro-inflammatory concerns with lipid nanoparticles. *Mol Ther.* 2022 Jun 1;30(6):2109-2110. doi: 10.1016/j.ymthe.2022.04.011.
86. Bates SM, Munson MJ, Trovisco V, Pereira S, Miller SR, Sabirsh A, Betts CJ, Blenke EO, Gay NJ. The kinetics of endosomal disruption reveal differences in lipid nanoparticle induced cellular toxicity. *J Control Release.* 2025 Oct 10;386:114047. doi: 10.1016/j.jconrel.2025.114047.
87. Su J, Song Y, Zhu Z, Huang X, Fan J, Qiao J, Mao F. Cell-cell communication: new insights and clinical implications. *Signal Transduct Target Ther.* 2024 Aug 7;9(1):196. doi: 10.1038/s41392-024-01888-z.
88. Bansal S, Perincheri S, Fleming T, Poulson C, Tiffany B, Bremner RM, Mohanakumar T. Cutting edge: Circulating exosomes with COVID spike protein are induced by BNT162b2 (Pfizer-BioNTech) vaccination prior to development of antibodies: A novel mechanism for immune activation by mRNA vaccines. *J Immunol.* 2021 Nov 15;207(10):2405-2410. doi: 10.4049/jimmunol.2100637.
89. Kammerer USV, Steger K. BioNTech RNA-based COVID-19 injections contain large amounts of residual DNA including an SV40 promoter/enhancer Sequence. *Journal of Science, Public Health Policy and the Law* 2024; v5.2019-2024.
90. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics--developing a new class of drugs. *Nat Rev Drug Discov.* 2014 Oct;13(10):759-80. doi: 10.1038/nrd4278.
91. Jörgensen AM, Wibel R, Bernkop-Schnürch A. Biodegradable cationic and ionizable cationic lipids: A roadmap for safer pharmaceutical excipients. *Small.* 2023 Apr;19(17):e2206968. doi: 10.1002/smll.202206968.

92. Knaggs KLM, Sun Y, Walz BA, Pang J, Khan OF. The role of excipients in lipid nanoparticle metabolism: implications for enhanced therapeutic effect. *Ther Deliv.* 2025 Jul;16(7):687-700. doi: 10.1080/20415990.2025.2506977.
93. Packer M, Gyawali D, Yerabolu R, Schariter J, White P. A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems. *Nat Commun* 2021; 12(1): 6777. doi: 10.1038/s41467-021-26926-0.
94. Moderna. Moderna Science and Technology Day. 2022. [https://s29.q4cdn.com/435878511/files/doc_presentations/2022/05/Science-Day-2022-Master-Slides-FINAL-\(05.17_7am\).pdf](https://s29.q4cdn.com/435878511/files/doc_presentations/2022/05/Science-Day-2022-Master-Slides-FINAL-(05.17_7am).pdf), 2022. (accessed February 28, 2023).
95. USFDA. Letter to Pfizer: Children's vaccination, authorization of formulation change. US Food and Drug Administration: <https://cacmap.fda.gov/media/150386/download>, 2021.
96. Maelfait J, Liverpool L, Rehwinkel J. Nucleic acid sensors and programmed cell death. *J Mol Biol.* 2020 Jan 17;432(2):552-568. doi: 10.1016/j.jmb.2019.11.016.
97. Fritz KS, Petersen DR. An overview of the chemistry and biology of reactive aldehydes. *Free Radic Biol Med.* 2013 Jun;59:85-91. doi: 10.1016/j.freeradbiomed.2012.06.025.
98. Dalleau S, Baradat M, Guéraud F, Huc L. Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance. *Cell Death Differ.* 2013 Dec;20(12):1615-30. doi: 10.1038/cdd.2013.138.
99. Hashiba K, Taguchi M, Sakamoto S, Otsu A, Maeda Y, Ebe H, Okazaki A, Harashima H, Sato Y. Overcoming thermostability challenges in mRNA-lipid nanoparticle systems with piperidine-based ionizable lipids. *Commun Biol.* 2024 May 10;7(1):556. doi: 10.1038/s42003-024-06235-0.
100. Wang W, Deng S, Lin J, Ouyang D. Modeling on in vivo disposition and cellular transportation of RNA lipid nanoparticles via quantum mechanics/physiologically-based pharmacokinetic approaches. *Acta Pharm Sin B.* 2024 Oct;14(10):4591-4607. doi: 10.1016/j.apsb.2024.06.011.
101. Yu Z, Li Q, Wang J, Yu Y, Wang Y, Zhou Q, Li P. Reactive oxygen species-related nanoparticle toxicity in the biomedical field. *Nanoscale Res Lett.* 2020 May 20;15(1):115. doi: 10.1186/s11671-020-03344-7.
102. Atianand MK, Fitzgerald KA. Molecular basis of DNA recognition in the immune system. *J Immunol.* 2013 Mar 1;190(5):1911-8. doi: 10.4049/jimmunol.1203162.
103. Szebeni J, Simberg D, González-Fernández Á, Barenholz Y, Dobrovolskaia MA. Roadmap and strategy for overcoming infusion reactions to nanomedicines. *Nat Nanotechnol.* 2018 Dec;13(12):1100-1108. doi: 10.1038/s41565-018-0273-1.
104. Bakos T, Mészáros T, Kozma GT, Berényi P, Facskó R, Farkas H, Dézsi L, Heirman C, de Koker S, Schiffelers R, Glatter KA, Radovits T, Szénási G, Szebeni J. mRNA-LNP COVID-19 vaccine lipids induce complement activation and production of proinflammatory cytokines: Mechanisms, effects of complement inhibitors, and relevance to adverse reactions. *Int J Mol Sci.* 2024 Mar 22;25(7):3595. doi: 10.3390/ijms25073595.
105. European Medicines Agency. Onpatro: European Public Assessment Report (EPAR) EMA/554262/2018. CHMP, Ed.; Amsterdam, NL, 2018.
106. Wang J, Ding Y, Chong K, Cui M, Cao Z, Tang C, Tian Z, Hu Y, Zhao Y, Jiang S. Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery. *Vaccines (Basel).* 2024 Oct 8;12(10):1148. doi: 10.3390/vaccines12101148.
107. Zhang L, Ren F, Zhang X, Wang X, Shi H, Zhou L, Zheng S, Chen Y, Chen D, Li L, Zhao C, Duan Z. Peroxisome proliferator-activated receptor alpha acts as a mediator of endoplasmic reticulum stress-induced hepatocyte apoptosis in acute liver failure. *Dis Model Mech.* 2016 Jul 1;9(7):799-809. doi: 10.1242/dmm.023242.
108. Popovics H, Mikone K, Mozes M, Kwon J-Y, Hansmann G, Kokeny G. P0721 PPAR-gamma activation inhibits TGF-beta induced renal complement and galectin-3 expression in vivo and in vitro, *Nephrology Dialysis Transplantation* 2020; 35(Suppl 3): gfaa142.P0721. doi: 10.1093/ndt/gfaa142.P0721.
109. Kong Y, Wang N, Tong Z, Wang D, Wang P, Yang Q, Yan X, Song W, Jin Z, Zhang M. Role of complement factor D in cardiovascular and metabolic diseases. *Front Immunol.* 2024 Oct 2;15:1453030. doi: 10.3389/fimmu.2024.1453030.
110. Pfizer/BioNTech. R&D STUDY REPORT No. R-20-0112 Characterizing the immunophenotype in spleen and lymph node of mice treated with SARS-CoV2 vaccine candidates. Report released by FOIA 1/2/23. 2020

- Sep 17. (Accessed on October 5, 2025.) https://phmpt.org/wp-content/uploads/2023/02/125742_S1_M4_4.2.1-r-20-0112.pdf.
111. Chaudhary N, Kasiewicz LN, Newby AN, Arral ML, Yerneni SS, Melamed JR, LoPresti ST, Fein KC, Strelkova Petersen DM, Kumar S, Purwar R, Whitehead KA. Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d. *Nat Biomed Eng.* 2024 Nov;8(11):1483-1498. doi: 10.1038/s41551-024-01256-w.
 112. Means N, Elechalawar CK, Chen WR, Bhattacharya R, Mukherjee P. Revealing macropinocytosis using nanoparticles. *Mol Aspects Med.* 2022 Feb;83:100993. doi: 10.1016/j.mam.2021.100993.
 113. Baimanov D, Wang J, Liu Y, Zheng P, Yu S, Liu F, Wang J, Boraschi D, Zhao Y, Chen C, Wang L. Identification of cell receptors responsible for recognition and binding of lipid nanoparticles. *Journal of the American Chemical Society* 2025; 147(9): 7604-7616. doi: 10.1021/jacs.4c16987.
 114. Paunovska K, Da Silva Sanchez AJ, Lokugamage MP, Loughrey D, Echeverri ES, Cristian A, Hatit MZC, Santangelo PJ, Zhao K, Dahlman JE. The extent to which lipid nanoparticles require apolipoprotein E and low-density lipoprotein receptor for delivery changes with ionizable lipid structure. *Nano Lett.* 2022 Dec 28;22(24):10025-10033. doi: 10.1021/acs.nanolett.2c03741.
 115. Karikó K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. *J Biol Chem.* 2004 Mar 26;279(13):12542-50. doi: 10.1074/jbc.M310175200.
 116. Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. *Mol Ther.* 2008 Nov;16(11):1833-40. doi: 10.1038/mt.2008.200.
 117. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity.* 2005 Aug;23(2):165-75. doi: 10.1016/j.immuni.2005.06.008.
 118. Monroe J, Eycler DE, Mitchell L, Deb I, Bojanowski A, Srinivas P, Dunham CM, Roy B, Frank AT, Koutmou KS. N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation. *Nat Commun.* 2024 Sep 16;15(1):8119. doi: 10.1038/s41467-024-51301-0.
 119. Przybylski S, Gasch M, Marschner A, Ebert M, Ewe A, Helmig G, Hilger N, Fricke S, Rudzok S, Aigner A, Burkhardt J. Influence of nanoparticle-mediated transfection on proliferation of primary immune cells in vitro and in vivo. *PLoS One.* 2017 May 2;12(5):e0176517. doi: 10.1371/journal.pone.0176517.
 120. Guo X, Wang H, Li Y, Leng X, Huang W, Ma Y, Xu T, Qi X. Transfection reagent Lipofectamine triggers type I interferon signaling activation in macrophages. *Immunol Cell Biol.* 2019 Jan;97(1):92-96. doi: 10.1111/imcb.12194. Epub 2018 Aug 31. Erratum in: *Immunol Cell Biol.* 2020 Jan;98(1):88. doi: 10.1111/imcb.12300.
 121. Choe U, Yu L, Wang TTY. Selected lipid-based transfection reagents activate NF- κ B and MAP kinases signaling pathways, induced cytokines mRNA expression in human THP-1 macrophage. *Anal Biochem.* 2019 May 15;573:73-76. doi: 10.1016/j.ab.2019.02.018.
 122. Connors J, Joyner D, Mege NJ, Cusimano GM, Bell MR, Marcy J, Taramangalam B, Kim KM, Lin PJC, Tam YK, Weissman D, Kutzler MA, Alameh MG, Haddad EK. Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals. *Commun Biol.* 2023 Feb 17;6(1):188. doi: 10.1038/s42003-023-04555-1. Erratum in: *Commun Biol.* 2025 Feb 22;8(1):285. doi: 10.1038/s42003-025-07603-0.
 123. Korzun T, Moses AS, Jozic A, Grigoriev V, Newton S, Kim J, Diba P, Sattler A, Levasseur PR, Le N, Singh P, Sharma KS, Goo YT, Mamnoon B, Raitmayr C, Mesquita Souza AP, Taratula OR, Sahay G, Taratula O, Marks DL. Lipid nanoparticles elicit reactogenicity and sickness behavior in mice via toll-like receptor 4 and myeloid differentiation protein 88 axis. *ACS Nano.* 2024 Sep 10;18(36):24842-24859. doi: 10.1021/acsnano.4c05088.
 124. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. *Immunity.* 2011 May 27;34(5):637-50. doi: 10.1016/j.immuni.2011.05.006.
 125. Ding X, Jin S, Tong Y, Jiang X, Chen Z, Mei S, Zhang L, Billiar TR, Li Q. TLR4 signaling induces TLR3 up-regulation in alveolar macrophages during acute lung injury. *Sci Rep* 2017; 7: 34278. doi: 10.1038/srep34278.

126. Nouri-Shirazi M, Tamjidi S, Nourishirazi E, Guinet E. Combination of TLR8 and TLR4 agonists reduces the degrading effects of nicotine on DC-NK mediated effector T cell generation. *Int Immunopharmacol.* 2018 Aug;61:54-63. doi: 10.1016/j.intimp.2018.05.012.
127. Kim HJ, Kim H, Lee JH, Hwangbo C. Toll-like receptor 4 (TLR4): new insight immune and aging. *Immun Ageing.* 2023 Nov 24;20(1):67. doi: 10.1186/s12979-023-00383-3.
128. Alhamdan F, Bayarsaikhan G, Yuki K. Toll-like receptors and integrins crosstalk. *Front Immunol.* 2024 Jun 10;15:1403764. doi: 10.3389/fimmu.2024.1403764.
129. Ghosh TK, Mickelson DJ, Solberg JC, Lipson KE, Inglefield JR, Alkan SS. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha. *Int Immunopharmacol.* 2007 Aug;7(8):1111-21. doi: 10.1016/j.intimp.2007.04.006.
130. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. *Circulation.* 2001 Dec 18;104(25):3103-8. doi: 10.1161/hc5001.100631.
131. Hovland A, Jonasson L, Garred P, Yndestad A, Aukrust P, Lappegård KT, Espevik T, Mollnes TE. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. *Atherosclerosis.* 2015 Aug;241(2):480-94. doi: 10.1016/j.atherosclerosis.2015.05.038.
132. Luo L, Wall AA, Tong SJ, Hung Y, Xiao Z, Tarique AA, Sly PD, Fantino E, Marzolo MP, Stow JL. TLR crosstalk activates LRP1 to recruit Rab8a and PI3K γ for suppression of inflammatory responses. *Cell Rep.* 2018 Sep 11;24(11):3033-3044. doi: 10.1016/j.celrep.2018.08.028.
133. Köberlin MS, Heinz LX, Superti-Furga G. Functional crosstalk between membrane lipids and TLR biology. *Curr Opin Cell Biol.* 2016 Apr;39:28-36. doi: 10.1016/j.ceb.2016.01.010.
134. Kornilov FD, Shabalkina AV, Lin C, Volynsky PE, Kot EF, Kayushin AL, Lushpa VA, Goncharuk MV, Arseniev AS, Goncharuk SA, Wang X, Mineev KS. The architecture of transmembrane and cytoplasmic juxtamembrane regions of Toll-like receptors. *Nat Commun.* 2023 Mar 17;14(1):1503. doi: 10.1038/s41467-023-37042-6.
135. Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igyártó BZ. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. *iScience.* 2021 Dec 17;24(12):103479. doi: 10.1016/j.isci.2021.103479.
136. Finney DJ. The median lethal dose and its estimation. *Arch Toxicol.* 1985 Feb;56(4):215-8. doi: 10.1007/BF00295156.
137. Avila AM, Bebenek I, Bonzo JA, Bourcier T, Davis Bruno KL, Carlson DB, Dubinion J, Elayan I, Harrouk W, Lee SL, Mendrick DL, Merrill JC, Peretz J, Place E, Saulnier M, Wange RL, Yao J, Zhao D, Brown PC. An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs). *Regul Toxicol Pharmacol.* 2020 Jul;114:104662. doi: 10.1016/j.yrtph.2020.104662.
138. Li GM. Mechanisms and functions of DNA mismatch repair. *Cell Res.* 2008 Jan;18(1):85-98. doi: 10.1038/cr.2007.115.
139. Molnár T., Mázló A., Tslaf V., Szöllösi A.G., Emri G., Koncz G. Current translational potential and underlying molecular mechanisms of necroptosis. *Cell Death Dis.* 2019;10 doi: 10.1038/s41419-019-2094-z.
140. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. *Pharmacol Ther.* 1995;68(3):385-424. doi: 10.1016/0163-7258(95)02013-6.
141. Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, Zeng C, Zhou T, Zhang J. NF- κ B in biology and targeted therapy: new insights and translational implications. *Signal Transduct Target Ther.* 2024 Mar 4;9(1):53. doi: 10.1038/s41392-024-01757-9.
142. Parameswaran N, Patial S. Tumor necrosis factor- α signaling in macrophages. *Crit Rev Eukaryot Gene Expr.* 2010;20(2):87-103. doi: 10.1615/critreveukargeneexpr.v20.i2.10.
143. Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. *Nat Rev Immunol.* 2023 Jan;23(1):38-54. doi: 10.1038/s41577-022-00746-9.

144. Wicherska-Pawłowska K, Wróbel T, Rybka J. Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases. *Int J Mol Sci.* 2021 Dec 13;22(24):13397. doi: 10.3390/ijms222413397.
145. Mohan GS, Kumar R. Impairment of tricarboxylic acid cycle (TCA) cycle in Alzheimer's disease: Mechanisms, implications, and potential therapies. *Aging Dis.* 2025 May 29;16(5):2553-2574. doi: 10.14336/AD.2025.0472.
146. Lee Y. Roles of circadian clocks in cancer pathogenesis and treatment. *Exp Mol Med* 2021; 53: 1529–1538. <https://doi.org/10.1038/s12276-021-00681-0>.
147. Dunn WG, McLoughlin MA, Vassiliou GS. Clonal hematopoiesis and hematological malignancy. *J Clin Invest.* 2024 Oct 1;134(19):e180065. doi: 10.1172/JCI180065.
148. Zheng Y, Sun L, Jiang T, Zhang D, He D, Nie H. TNF α promotes Th17 cell differentiation through IL-6 and IL-1 β produced by monocytes in rheumatoid arthritis. *J Immunol Res.* 2014;2014:385352. doi: 10.1155/2014/385352.
149. Marasco MR, Conteh AM, Reissaus CA, Cupit JE 5th, Appleman EM, Mirmira RG, Linnemann AK. Interleukin-6 reduces β -cell oxidative stress by linking autophagy with the antioxidant response. *Diabetes.* 2018 Aug;67(8):1576-1588. doi: 10.2337/db17-1280.
150. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. *Nat Rev Immunol.* 2013 Oct;13(10):722-37. doi: 10.1038/nri3532.
151. Chi DS, Fitzgerald SM, Pitts S, Cantor K, King E, Lee SA, Huang SK, Krishnaswamy G. MAPK-dependent regulation of IL-1- and beta-adrenoreceptor-induced inflammatory cytokine production from mast cells: implications for the stress response. *BMC Immunol.* 2004 Sep 21;5:22. doi: 10.1186/1471-2172-5-22.
152. Yang HT, Cohen P, Rousseau S. IL-1 β -stimulated activation of ERK1/2 and p38 α MAPK mediates the transcriptional up-regulation of IL-6, IL-8 and GRO- α in HeLa cells. *Cell Signal.* 2008 Feb;20(2):375-80. doi: 10.1016/j.cellsig.2007.10.025.
153. Tengesdal IW, Dinarello A, Powers NE, Burchill MA, Joosten LAB, Marchetti C, Dinarello CA. Tumor NLRP3-derived IL-1 β drives the IL-6/STAT3 axis resulting in sustained MDSC-mediated immunosuppression. *Front Immunol.* 2021 Aug 31;12:661323. doi: 10.3389/fimmu.2021.661323.
154. Li H, Wu M, Zhao X. Role of chemokine systems in cancer and inflammatory diseases. *MedComm* (2020). 2022 Jun 8;3(2):e147. doi: 10.1002/mco2.147.
155. Unver N. Macrophage chemoattractants secreted by cancer cells: Sculptors of the tumor microenvironment and another crucial piece of the cancer secretome as a therapeutic target. *Cytokine Growth Factor Rev.* 2019 Dec;50:13-18. doi: 10.1016/j.cytogfr.2019.05.010.
156. Nakatsumi H, Matsumoto M, Nakayama KI. Noncanonical pathway for regulation of CCL2 expression by an mTORC1-FOXK1 axis promotes recruitment of tumor-associated macrophages. *Cell Rep.* 2017 Nov 28;21(9):2471-2486. doi: 10.1016/j.celrep.2017.11.014.
157. Huda N, Khambu B, Liu G, Nakatsumi H, Yan S, Chen X, Ma M, Dong Z, Nakayama KI, Yin XM. Senescence connects autophagy deficiency to inflammation and tumor progression in the liver. *Cell Mol Gastroenterol Hepatol.* 2022;14(2):333-355. doi: 10.1016/j.jcmgh.2022.04.003.
158. Forster III J, Nandi D, Kulkarni A. mRNA-carrying lipid nanoparticles that induce lysosomal rupture activate NLRP3 inflammasome and reduce mRNA transfection efficiency. *Biomater Sci.* 2022 Sep 27;10(19):5566-5582. doi: 10.1039/d2bm00883a.
159. Shin JN, Rao L, Sha Y, Abdel Fattah E, Hyser J, Eissa NT. p38 MAPK activity is required to prevent hyperactivation of NLRP3 inflammasome. *J Immunol.* 2021 Jul 15;207(2):661-670. doi: 10.4049/jimmunol.2000416.
160. Lv JM, Gao YL, Wang LY, Li BD, Shan YL, Wu ZQ, Lu QM, Peng HY, Zhou TT, Li XM, Zhang LM. Inhibition of the P38 MAPK/NLRP3 pathway mitigates cognitive dysfunction and mood alterations in aged mice after abdominal surgery plus sevoflurane. *Brain Res Bull.* 2024 Oct 15;217:111059. doi: 10.1016/j.brainresbull.2024.111059.
161. Sozio MS, Lu C, Zeng Y, Liangpunsakul S, Crabb DW. Activated AMPK inhibits PPAR- α and PPAR- γ transcriptional activity in hepatoma cells. *Am J Physiol Gastrointest Liver Physiol.* 2011 Oct;301(4):G739-47. doi: 10.1152/ajpgi.00432.2010.

162. Sun H, Zhu X, Lin W, Zhou Y, Cai W, Qiu L. Interactions of TLR4 and PPAR γ , dependent on AMPK signalling pathway contribute to anti-inflammatory effects of vaccariae hypaphorine in endothelial cells. *Cell Physiol Biochem*. 2017;42(3):1227-1239. doi: 10.1159/000478920.
163. Harada K, Isse K, Kamihira T, Shimoda S, Nakanuma Y. Th1 cytokine-induced downregulation of PPAR γ in human biliary cells relates to cholangitis in primary biliary cirrhosis. *Hepatology*. 2005 Jun;41(6):1329-38. doi: 10.1002/hep.20705.
164. Yin R, Dong YG, Li HL. PPAR γ phosphorylation mediated by JNK MAPK: a potential role in macrophage-derived foam cell formation. *Acta Pharmacol Sin*. 2006 Sep;27(9):1146-52. doi: 10.1111/j.1745-7254.2006.00359.x.
165. Su AC, Zhang LY, Zhang JG, Hu YY, Liu XY, Li SC, Xian XH, Li WB, Zhang M. The regulation of autophagy by p38 MAPK-PPAR γ signaling during the brain ischemic tolerance induced by cerebral ischemic preconditioning. *DNA Cell Biol*. 2022 Sep;41(9):838-849. doi: 10.1089/dna.2022.0087.
166. Ballav S, Biswas B, Sahu VK, Ranjan A, Basu S. PPAR γ partial agonists in disease-fate decision with special reference to cancer. *Cells*. 2022 Oct 13;11(20):3215. doi: 10.3390/cells11203215.
167. Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, Qin S. Cytochrome P450 enzymes and drug metabolism in humans. *Int J Mol Sci*. 2021 Nov 26;22(23):12808. doi: 10.3390/ijms222312808.
168. Liu F, Aulin LBS, Manson ML, Krekels EHJ, van Hasselt JGC. Unraveling the effects of acute inflammation on pharmacokinetics: A model-based analysis focusing on renal glomerular filtration rate and cytochrome P450 3A4-mediated metabolism. *Eur J Drug Metab Pharmacokinet*. 2023 Nov;48(6):623-631. doi: 10.1007/s13318-023-00852-6.
169. Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R; French Society of Pharmacology and Therapeutics. Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment. *Pharmacol Ther*. 2020 Nov;215:107627. doi: 10.1016/j.pharmthera.2020.107627.
170. Bayraktar İ, Yalçın N, Demirkan K. The potential interaction between COVID-19 vaccines and clozapine: A novel approach for clinical trials. *Int J Clin Pract*. 2021 Aug;75(8):e14441. doi: 10.1111/ijcp.14441.
171. Imai T, Ochiai S, Ishimaru T, Daitoku H, Miyagawa Y, Fukuhara R, Boku S, Takebayashi M. A case report: Clozapine-induced leukopenia and neutropenia after mRNA COVID-19 vaccination. *Neuropsychopharmacol Rep*. 2022 Jun;42(2):238-240. doi: 10.1002/npr2.12238.
172. Thompson D, Delorme CM, White RF, Honer WG. Elevated clozapine levels and toxic effects after SARS-CoV-2 vaccination. *J Psychiatry Neurosci*. 2021 Mar 5;46(2):E210-E211. doi: 10.1503/jpn.210027.
173. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. *Br J Clin Pharmacol*. 1997 Nov;44(5):439-46. doi: 10.1046/j.1365-2125.1997.t01-1-00605.x.
174. Villemure S, Trenaman SC, Goralski KB. The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions. *Expert Opin Drug Metab Toxicol*. 2023 Jan-Jun;19(6):329-332. doi: 10.1080/17425255.2023.2228680.
175. Lim SYM, Al Bishtawi B, Lim W. Role of cytochrome P450 2C9 in COVID-19 treatment: Current status and future directions. *Eur J Drug Metab Pharmacokinet*. 2023 May;48(3):221-240. doi: 10.1007/s13318-023-00826-8.
176. Szychowski KA, Skóra B, Wójtowicz AK. Engagement of peroxisome proliferator-activated receptor γ (PPAR γ) and mammalian target of rapamycin (mTOR) in the triclosan-induced disruption of Cyp450 enzyme activity in an in vitro model of mouse embryo fibroblasts (3T3-L1). *Toxicology*. 2025 Feb;511:154031. doi: 10.1016/j.tox.2024.154031.
177. Hossam Abdelmonem B, Abdelaal NM, Anwer EKE, Rashwan AA, Hussein MA, Ahmed YF, Khashana R, Hanna MM, Abdelnaser A. Decoding the role of CYP450 enzymes in metabolism and disease: A comprehensive review. *Biomedicines*. 2024 Jul 2;12(7):1467. doi: 10.3390/biomedicines12071467.
178. Koozi H, Lengquist M, Frigyesi A. C-reactive protein as a prognostic factor in intensive care admissions for sepsis: A Swedish multicenter study. *J Crit Care*. 2020 Apr;56:73-79. doi: 10.1016/j.jcrc.2019.12.009.

179. Lenoir C, Rollason V, Desmeules JA, Samer CF. Influence of inflammation on cytochromes P450 activity in adults: A systematic review of the literature. *Front Pharmacol.* 2021 Nov 16;12:733935. doi: 10.3389/fphar.2021.733935.
180. Li Q, Zheng Y, Sun Y, Xu G. Resveratrol attenuated fatty acid synthesis through MAPK-PPAR pathway in red tilapia. *Comp Biochem Physiol C Toxicol Pharmacol.* 2023 Jun;268:109598. doi: 10.1016/j.cbpc.2023.109598.
181. Shveygert M, Kaiser C, Bradrick SS, Gromeier M. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction. *Mol Cell Biol.* 2010 Nov;30(21):5160-7. doi: 10.1128/MCB.00448-10.
182. Lin Y, Bian L, Zhu G, Zhang B. Vitronectin promotes proliferation and metastasis of cervical cancer cells via the epithelial-mesenchymal transition. *Front Oncol.* 2024 Dec 9;14:1466264. doi: 10.3389/fonc.2024.1466264.
183. Gao P, Lu Y, Tang K, Wang W, Wang T, Zhu Y, Zhao J, Mao Y. Ficolin-1 ameliorates pulmonary fibrosis via directly binding to TGF- β 1. *J Transl Med.* 2024 Nov 21;22(1):1051. doi: 10.1186/s12967-024-05894-1.
184. Knabl L, Lee HK, Wieser M, Mur A, Zabernigg A, Knabl L Sr, Rauch S, Bock M, Schumacher J, Kaiser N, Furth PA, Hennighausen L. BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant. *Commun Med (Lond).* 2022;2(1):17. doi: 10.1038/s43856-022-00083-x.
185. Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. *Cancer.* 2014 Nov 15;120(22):3446-56. doi: 10.1002/cncr.28864.
186. Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, Sengupta S, Kumar D, Garg M. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. *Signal Transduct Target Ther.* 2023 Oct 2;8(1):375. doi: 10.1038/s41392-023-01608-z.
187. Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF- κ B pathway for the therapy of diseases: mechanism and clinical study. *Signal Transduct Target Ther.* 2020 Sep 21;5(1):209. doi: 10.1038/s41392-020-00312-6.
188. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. *Oncotarget.* 2012 Sep;3(9):954-87. doi: 10.18632/oncotarget.652.
189. Nigam M, Punia B, Dimri DB, Mishra AP, Radu AF, Bungau G. Reactive oxygen species: A double-edged sword in the modulation of cancer signaling pathway dynamics. *Cells.* 2025 Aug 6;14(15):1207. doi: 10.3390/cells14151207.
190. Cui D, Qu R, Liu D, Xiong X, Liang T, Zhao Y. The cross talk between p53 and mTOR pathways in response to physiological and genotoxic stresses. *Front Cell Dev Biol.* 2021 Nov 18;9:775507. doi: 10.3389/fcell.2021.775507.
191. Bassermann F, Eichner R, Pagano M. The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer. *Biochim Biophys Acta.* 2014 Jan;1843(1):150-62. doi: 10.1016/j.bbamcr.2013.02.028.
192. Chen Y, Gong W, Dai W, Jiang H, Xu X. E2F1/2/4 mRNA is associated with immune infiltration and are potential biomarkers for the prognosis of human gastric carcinoma. *Transl Cancer Res.* 2021 Jun;10(6):2801-2811. doi: 10.21037/tcr-21-45.
193. Daigh LH, Saha D, Rosenthal DL, Ferrick KR, Meyer T. Uncoupling of mTORC1 from E2F activity maintains DNA damage and senescence. *Nat Commun* 2024; 15: 9181. doi: 10.1038/s41467-024-52820-6.
194. Zhang Y, Hao X, Han G, Lu Y, Chen Z, Zhang L, Wu J, Wang X. E2F1-mediated GINS2 transcriptional activation promotes tumor progression through PI3K/AKT/mTOR pathway in hepatocellular carcinoma. *Am J Cancer Res.* 2022 Apr 15;12(4):1707-1726.
195. Calzone L, Gelay A, Zinovyev A, Radvanyi F, Barillot E. A comprehensive modular map of molecular interactions in RB/E2F pathway. *Mol Syst Biol.* 2008;4:173. doi: 10.1038/msb.2008.7.

196. Bertonnier-Brouly L, Andersson J, Kaprio T, Hagström J, Bsharat S, Asplund O, Hatem G, Haglund C, Seppänen H, Prasad RB, Artner I. E2F transcription factors promote tumorigenicity in pancreatic ductal adenocarcinoma. *Cancer Med.* 2024 May;13(9):e7187. doi: 10.1002/cam4.7187.
197. Wasserman D, Nachum S, Cohen M, Enrico TP, Noach-Hirsh M, Parasol J, Zomer-Polak S, Auerbach N, Sheinberger-Chorni E, Nevenzal H, Levi-Dadon N, Wang X, Lahmi R, Michaely E, Gerber D, Emanuele MJ, Tzur A. Cell cycle oscillators underlying orderly proteolysis of E2F8. *Mol Biol Cell.* 2020 Apr 1;31(8):725-740. doi: 10.1091/mbc.E19-12-0725.
198. Timmers C, Sharma N, Opavsky R, Maiti B, Wu L, Wu J, Orringer D, Trikha P, Saavedra HI, Leone G. E2f1, E2f2, and E2f3 control E2F target expression and cellular proliferation via a p53-dependent negative feedback loop. *Mol Cell Biol.* 2007 Jan;27(1):65-78. doi: 10.1128/MCB.02147-05. Erratum in: *Mol Cell Biol.* 2012 May;32(9):1758.
199. Spitschak A, Dhar P, Singh KP, Casalegno Garduño R, Gupta SK, Vera J, Musella L, Murr N, Stoll A, Pützer BM. E2F1-induced autocrine IL-6 inflammatory loop mediates cancer-immune crosstalk that predicts T cell phenotype switching and therapeutic responsiveness. *Front Immunol.* 2024 Oct 31;15:1470368. doi: 10.3389/fimmu.2024.1470368.
200. Li J, Ran C, Li E, Gordon F, Comstock G, Siddiqui H, Cleghorn W, Chen HZ, Kornacker K, Liu CG, Pandit SK, Khanizadeh M, Weinstein M, Leone G, de Bruin A. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. *Dev Cell.* 2008 Jan;14(1):62-75. doi: 10.1016/j.devcel.2007.10.017.
201. Zheng J, Huang J, Xia J, Zhou W, Dai L, Lin S, Gao L, Zou C. Transcription factor E2F8 is a therapeutic target in the basal-like subtype of breast cancer. *Front Oncol.* 2023 Feb 6;13:1038787. doi: 10.3389/fonc.2023.1038787.
202. Vigo E, Müller H, Prosperini E, Hateboer G, Cartwright P, Moroni MC, Helin K. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. *Mol Cell Biol.* 1999 Sep;19(9):6379-95. doi: 10.1128/MCB.19.9.6379.
203. Delgado M, Washam CL, Urbaniak A, Heflin B, Storey AJ, Lan RS, Mackintosh SG, Tackett AJ, Byrum SD, Chambers TC. Phosphoproteomics provides novel insights into the response of primary acute lymphoblastic leukemia cells to microtubule depolymerization in G1 phase of the cell cycle. *ACS Omega.* 2021 Sep 16;6(38):24949-24959. doi: 10.1021/acsomega.1c03936.
204. Knapp JD, Bhargava A. BNT162b2 mRNA vaccine-induced sex differences in the single-cell transcriptome of peripheral blood mononuclear cells in healthy adults bioRxiv Preprint. Oct 3, 2023. doi: 10.1101/2023.10.02.560569.
205. Ezine E, Lebbe C, Dumaz N. Unmasking the tumourigenic role of SIN1/MAPKAP1 in the mTOR complex 2. *Clin Transl Med.* 2023 Oct;13(10):e1464. doi: 10.1002/ctm2.1464.
206. Hickey TE, Mudunuri U, Hempel HA, Kemp TJ, Roche NV, Talsania K, Sellers BA, Cherry JM, Pinto LA. Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera. *Front Immunol.* 2025 Jan 27;15:1502458. doi: 10.3389/fimmu.2024.1502458.
207. Savelsbergh A, Mohr D, Wilden B, Wintermeyer W, Rodnina MV. Stimulation of the GTPase activity of translation elongation factor G by ribosomal protein L7/12. *J Biol Chem.* 2000 Jan 14;275(2):890-4. doi: 10.1074/jbc.275.2.890.
208. Chang EC, Philips MR. Spatial segregation of Ras signaling: New evidence from fission yeast. *Cell Cycle.* 2006 Sep;5(17):1936-9. doi: 10.4161/cc.5.17.3187.
209. Fadhal E. The significance of key proteins in the RAS signaling pathway: Implications for cancer and therapeutic targets. *OBM Genetics* 2024; 8(2): 236; doi: 10.21926/obm.genet.2402236.
210. Lin Y, Parajón E, Yuan Q, Ye S, Qin G, Deng Y, Borleis J, Koyfman A, Iglesias PA, Konstantopoulos K, Robinson DN, Devreotes PN. Ras-mediated dynamic and biphasic regulation of cell migration. *Proc Natl Acad Sci U S A.* 2025 Jul 29;122(30):e2503847122. doi: 10.1073/pnas.2503847122.
211. Chippalkatti R, Parisi B, Kouzi F, Laurini C, Ben Fredj N, Abankwa DK. RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation. *Eur J Cell Biol.* 2024 Jun;103(2):151425. doi: 10.1016/j.ejcb.2024.151425.

212. Wang YF, Dong ZK, Jin WL. Hijacking homeostasis: the brain-body neural circuitry in tumor pathogenesis and emerging therapeutic frontiers. *Mol Cancer*. 2025 Jul 25;24(1):206. doi: 10.1186/s12943-025-02396-6.
213. Peng Q, Li X, Fang C, Zhu C, Wang T, Yin B, Dong X, Guo H, Liu Y, Zhang K. Disrupting calcium homeostasis and glycometabolism in engineered lipid-based pharmaceuticals propel cancer immunogenic death. *Acta Pharm Sin B*. 2025 Mar;15(3):1255-1267. doi: 10.1016/j.apsb.2024.12.018.
214. Gulluni F, Martini M, Hirsch E. Cytokinetic Abscission: Phosphoinositides and ESCRTs direct the final cut. *J Cell Biochem*. 2017 Nov;118(11):3561-3568. doi: 10.1002/jcb.26066. Erratum in: *J Cell Biochem*. 2024 Aug;125(8):e30626. doi: 10.1002/jcb.30626.
215. Tan X, Thapa N, Choi S, Anderson RA. Emerging roles of PtdIns(4,5)P₂--beyond the plasma membrane. *J Cell Sci*. 2015 Nov 15;128(22):4047-56. doi: 10.1242/jcs.175208.
216. Ajazi A, Bruhn C, Shubassi G, Lucca C, Ferrari E, Cattaneo A, Bachi A, Manfrini N, Biffo S, Martini E, Minucci S, Vernieri C, Foiani M. Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis. *Dev Cell*. 2021 Sep 27;56(18):2607-2622.e6. doi: 10.1016/j.devcel.2021.08.019.
217. Hurley JH, Coyne AN, Międzyńska M, Stenmark H. The expanding repertoire of ESCRT functions in cell biology and disease. *Nature* 2025; 642: 877–888. doi: 10.1038/s41586-025-08950-y.
218. Zhu L, Jorgensen JR, Li M, Chuang YS, Emr SD. ESCRTs function directly on the lysosome membrane to downregulate ubiquitinated lysosomal membrane proteins. *Elife*. 2017 Jun 29;6:e26403. doi: 10.7554/eLife.26403.
219. Jia S, Yang Y, Liu J, Wang Z, Bai L. PPAR γ controls ESCRT-dependent fibroblast-like synoviocyte exosome biogenesis and alleviates chondrocyte osteoarthritis mediated by exosomal ANXA1. *J Orthop Translat*. 2025 Jun 27;53:187-205. doi: 10.1016/j.jot.2025.06.008.
220. Simonsen JB. A perspective on bleb and empty LNP structures. *J Control Release*. 2024 Sep;373:952-961. doi: 10.1016/j.jconrel.2024.07.046.
221. Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, Crommelin DJA. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. *Int J Pharm*. 2021 May 15;601:120586. doi: 10.1016/j.ijpharm.2021.120586.
222. Liao S, Wang S, Wadhwa A, Birkenshaw A, Fox K, Cheng MHY, Casmil IC, Magana AA, Bathula NV, Ho CH, Cheng JY, Foster LJ, Harder KW, Ross CJD, Cullis PR, Blakney AK. Transfection potency of lipid nanoparticles containing mRNA depends on relative loading levels. *ACS Appl Mater Interfaces*. 2025 Jan 15;17(2):3097-3105. doi: 10.1021/acsami.4c20077.
223. Loney C, Vandenbranden M, Ruysschaert JM. Cationic liposomal lipids: from gene carriers to cell signaling. *Prog Lipid Res*. 2008 Sep;47(5):340-7. doi: 10.1016/j.plipres.2008.03.002.
224. Loney C, Vandenbranden M, Ruysschaert JM. Cationic lipids activate intracellular signaling pathways. *Adv Drug Deliv Rev*. 2012 Dec;64(15):1749-58. doi: 10.1016/j.addr.2012.05.009.
225. Qin Z, Bouteau A, Herbst C, Igyártó BZ. Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion. *PLoS Pathog*. 2022 Sep 2;18(9):e1010830. doi: 10.1371/journal.ppat.1010830.
226. Sellegounder D, Ferrucci L, Anbazhagan R, Basisty N. Editorial: Molecular crosstalk between endocrine factors, paracrine signals, and the immune system during aging. *Front Endocrinol (Lausanne)*. 2023 Apr 21;14:1203755. doi: 10.3389/fendo.2023.1203755.
227. Panariti A, Misericocchi G, Rivolta I. The effect of nanoparticle uptake on cellular behavior: disrupting or enabling functions? *Nanotechnol Sci Appl*. 2012 Sep 7;5:87-100. doi: 10.2147/NSA.S25515.
228. Voigt J, Christensen J, Shastri VP. Differential uptake of nanoparticles by endothelial cells through polyelectrolytes with affinity for caveolae. *Proc Natl Acad Sci U S A*. 2014 Feb 25;111(8):2942-7. doi: 10.1073/pnas.1322356111.
229. Wang T, Bai J, Jiang X, Nienhaus GU. Cellular uptake of nanoparticles by membrane penetration: a study combining confocal microscopy with FTIR spectroelectrochemistry. *ACS Nano*. 2012 Feb 28;6(2):1251-9. doi: 10.1021/nn203892h.
230. Gerelli Y. Chapter Three: Exploring interactions between lipid membranes and nanoparticles through neutron and X-ray reflectometry techniques. In A. Iglič, M. Rappolt, & P. Losada-Pérez (Eds.), *Advances in*

- Biomembranes and Lipid Self-Assembly 2023; 38: 37–61. Academic Press. <https://doi.org/10.1016/bs.abl.2023.07.001>.
231. Lavagna E, Barnoud J, Rossi G, Monticelli L. Size-dependent aggregation of hydrophobic nanoparticles in lipid membranes. *Nanoscale* 2020; 12: 9452–9461. doi: 10.1039/d0nr00868k.
 232. Cooper GM. *The Cell: A Molecular Approach*. 2nd edition. Sunderland (MA): Sinauer Associates; 2000.
 233. Hammond GRV, Burke JE. Novel roles of phosphoinositides in signaling, lipid transport, and disease. *Curr Opin Cell Biol.* 2020 Apr;63:57-67. doi: 10.1016/j.ceb.2019.12.007.
 234. Skotland T, Sandvig K. The role of PS 18:0/18:1 in membrane function. *Nat Commun.* 2019 Jun 21;10(1):2752. doi: 10.1038/s41467-019-10711-1.
 235. Heimbürg T. The excitable fluid mosaic. *Biochim Biophys Acta Biomembr.* 2023 Mar;1865(3):184104. doi: 10.1016/j.bbamem.2022.184104.
 236. Lupyan D, Mezei M, Logothetis DE, Osman R. A molecular dynamics investigation of lipid bilayer perturbation by PIP2. *Biophys J.* 2010 Jan 20;98(2):240-7. doi: 10.1016/j.bpj.2009.09.063.
 237. Pike LJ. Lipid rafts: bringing order to chaos. *J Lipid Res.* 2003 Apr;44(4):655-67. doi: 10.1194/jlr.R200021-JLR200.
 238. Levin R, Grinstein S, Schlam D. Phosphoinositides in phagocytosis and macropinocytosis. *Biochim Biophys Acta.* 2015 Jun;1851(6):805-23. doi: 10.1016/j.bbailip.2014.09.005.
 239. Weiner OD, Neilsen PO, Prestwich GD, Kirschner MW, Cantley LC, Bourne HR. A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. *Nat Cell Biol.* 2002 Jul;4(7):509-13. doi: 10.1038/ncb811.
 240. Guan K, Curtis ER, Lew DJ, Elston TC. Particle-based simulations reveal two positive feedback loops allow relocation and stabilization of the polarity site during yeast mating. *PLoS Comput Biol.* 2023 Oct 2;19(10):e1011523. doi: 10.1371/journal.pcbi.1011523.
 241. Fallahi-Sichani M, Linderman JJ. Lipid raft-mediated regulation of G-protein coupled receptor signaling by ligands which influence receptor dimerization: a computational study. *PLoS One.* 2009 Aug 11;4(8):e6604. doi: 10.1371/journal.pone.0006604.
 242. Wang X, Shi X, Wang R. Regulating mRNA endosomal escape through lipid rafts: A review. *Int J Pharm.* 2025 Apr 30;675:125571. doi: 10.1016/j.ijpharm.2025.125571.
 243. Posor Y, Jang W, Haucke V. Phosphoinositides as membrane organizers. *Nat Rev Mol Cell Biol.* 2022 Dec;23(12):797-816. doi: 10.1038/s41580-022-00490-x.
 244. van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. *Nat Rev Mol Cell Biol.* 2008 Feb;9(2):112-24. doi: 10.1038/nrm2330.
 245. Lolicato F, Nickel W, Haucke V, Ebner M. Phosphoinositide switches in cell physiology - From molecular mechanisms to disease. *J Biol Chem.* 2024 Mar;300(3):105757. doi: 10.1016/j.jbc.2024.105757.
 246. Balla T. Phosphoinositides: tiny lipids with giant impact on cell regulation. *Physiol Rev.* 2013 Jul;93(3):1019-137. doi: 10.1152/physrev.00028.2012.
 247. Kjos I, Vestre K, Guadagno NA, Borg Distefano M, Progida C. Rab and Arf proteins at the crossroad between membrane transport and cytoskeleton dynamics. *Biochim Biophys Acta Mol Cell Res.* 2018 Jul 17;1865(10):1397-1409. doi: 10.1016/j.bbamcr.2018.07.009.
 248. Koike S, Jahn R. Rab GTPases and phosphoinositides fine-tune SNAREs dependent targeting specificity of intracellular vesicle traffic. *Nat Commun.* 2024 Mar 20;15(1):2508. doi: 10.1038/s41467-024-46678-x.
 249. Eramo MJ, Mitchell CA. Regulation of PtdIns(3,4,5)P3/Akt signalling by inositol polyphosphate 5-phosphatases. *Biochem Soc Trans.* 2016 Feb;44(1):240-52. doi: 10.1042/BST20150214.
 250. Nishimura T, Gecht M, Covino R, Hummer G, Surma MA, Klose C, Arai H, Kono N, Stefan CJ. Osh proteins control nanoscale lipid organization necessary for PI(4,5)P2 synthesis. *Mol Cell.* 2019 Sep 5;75(5):1043-1057.e8. doi: 10.1016/j.molcel.2019.06.037.
 251. Heckle LA, Kozminski KG. Osh-dependent and -independent regulation of PI4P levels during polarized growth of *Saccharomyces cerevisiae*. *Molecular Biology of the Cell* Sep 2023; 34(11). [Epub ahead of print].
 252. Raychaudhuri S, Prinz WA. The diverse functions of oxysterol-binding proteins. *Annu Rev Cell Dev Biol.* 2010;26:157-77. doi: 10.1146/annurev.cellbio.042308.113334.

253. Omo-Lamai S, Wang Y, Patel MN, Essien E-O, Shen M, Majumdar A, Espy C, Wu J, Channer B, Tobin M, Murali S, Papp TE, Maheshwari R, Wang L, Chase LS, Zamora ME, Arral ML, Marcos-Contreras OA, Myerson JW, Hunter CA, Tsourkas A, Muzykantov V, Brodsky I, Shin S, Whitehead KA, Gaskill P, Discher D, Parhiz H, Brenner JS. Lipid nanoparticle-associated inflammation is triggered by sensing of endosomal damage: Engineering endosomal escape without side effects. *bioRxiv preprint*. April 18, 2024. doi: <https://doi.org/10.1101/2024.04.16.589801>.
254. Cheng Y, Zhao E, Yang X, Luo C, Zi G, Wang R, Xu Y, Peng B. Entrapment of lipid nanoparticles in peripheral endosomes but not lysosomes impairs intracellular trafficking and endosomal escape. *Int J Pharm*. 2025 Jan 25;669:125024. doi: [10.1016/j.ijpharm.2024.125024](https://doi.org/10.1016/j.ijpharm.2024.125024).
255. Puranik A, Lenehan PJ, Silvert E, Niesen MJM, Corchado-Garcia J, O'Horo JC, Virk A, Swift MD, Gordon JE, Speicher LL, Geyer HL, Kremers W, Halamka J, Badley AD, Venkatakrishnan AJ, Soundararajan V. Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. *Med*. 2022 Jan 14;3(1):28-41.e8. doi: [10.1016/j.medj.2021.12.002](https://doi.org/10.1016/j.medj.2021.12.002).
256. Granados-Riveron JT, Aquino-Jarquín G. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. *Biomed Pharmacother*. 2021 Oct;142:111953. doi: [10.1016/j.biopha.2021.111953](https://doi.org/10.1016/j.biopha.2021.111953).
257. Harvey RD, Ara N, Heenan RK, Barlow DJ, Quinn PJ, Lawrence MJ. Stabilization of distearoylphosphatidylcholine lamellar phases in propylene glycol using cholesterol. *Mol Pharm*. 2013 Dec 2;10(12):4408-17. doi: [10.1021/mp400140u](https://doi.org/10.1021/mp400140u). Epub 2013 Nov 19.
258. Skotland T, Kavaliauskiene S, Sandvig K. The role of lipid species in membranes and cancer-related changes. *Cancer Metastasis Rev*. 2020 Jun;39(2):343-360. doi: [10.1007/s10555-020-09872-z](https://doi.org/10.1007/s10555-020-09872-z).
259. Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, Deng Y. A review on phospholipids and their main applications in drug delivery systems. *Asian Journal of Pharmaceutical Sciences* 2015; 10(2): 81-98. doi: [10.1016/j.ajps.2014.09.004](https://doi.org/10.1016/j.ajps.2014.09.004).
260. McMaster CR. From yeast to humans - roles of the Kennedy pathway for phosphatidylcholine synthesis. *FEBS Lett*. 2018 Apr;592(8):1256-1272. doi: [10.1002/1873-3468.12919](https://doi.org/10.1002/1873-3468.12919).
261. Cummings R, Parinandi N, Wang L, Usatyuk P, Natarajan V. Phospholipase D/phosphatidic acid signal transduction: role and physiological significance in lung. *Mol Cell Biochem*. 2002 May-Jun;234-235(1-2):99-109.
262. Wagner K, Brezesinski G. Phospholipase D activity is regulated by product segregation and the structure formation of phosphatidic acid within model membranes. *Biophys J*. 2007 Oct 1;93(7):2373-83. doi: [10.1529/biophysj.107.108787](https://doi.org/10.1529/biophysj.107.108787).
263. Bruntz RC, Lindsley CW, Brown HA. Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer. *Pharmacol Rev*. 2014 Oct;66(4):1033-79. doi: [10.1124/pr.114.009217](https://doi.org/10.1124/pr.114.009217).
264. Semenkovich CF, Goldberg AC, Goldberg IJ. Disorders of Lipid Metabolism. Chapter 37 in Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, Eds. *Williams Textbook of Endocrinology (Thirteenth Edition)*. Elsevier 2016: 1660-1700. doi: [10.1016/B978-0-323-29738-7.00037-X](https://doi.org/10.1016/B978-0-323-29738-7.00037-X).
265. Blunsom NJ, Cockcroft S. Phosphatidylinositol synthesis at the endoplasmic reticulum. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2020 Jan;1865(1):158471. doi: [10.1016/j.bbalip.2019.05.015](https://doi.org/10.1016/j.bbalip.2019.05.015).
266. Pearce B, Jakobson K, Morrow C, Murphy S. Phosphatidic acid promotes phosphoinositide metabolism and DNA synthesis in cultured cortical astrocytes. *Neurochem Int*. 1994 Feb;24(2):165-71. doi: [10.1016/0197-0186\(94\)90103-1](https://doi.org/10.1016/0197-0186(94)90103-1).
267. Quick J, Santos ND, Cheng MHY, Chander N, Brimacombe CA, Kulkarni J, van der Meel R, Tam YYC, Witzigmann D, Cullis PR. Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy. *J Control Release*. 2022 Sep;349:174-183. doi: [10.1016/j.jconrel.2022.06.051](https://doi.org/10.1016/j.jconrel.2022.06.051).
268. Jeschek D, Lhota G, Wallner J, Vorauer-Uhl K. A versatile, quantitative analytical method for pharmaceutical relevant lipids in drug delivery systems. *J Pharm Biomed Anal*. 2016 Feb 5;119:37-44. doi: [10.1016/j.jpba.2015.11.020](https://doi.org/10.1016/j.jpba.2015.11.020).
269. Rezaei S, Blick EE, Mineart KP, Kelley EG. Chapter Three - Linking chemical degradation and physical instability of lipid vesicles. *Advances in Biomembranes and Lipid Self-Assembly* 2025; 41: 47-64. doi: [10.1016/bs.abl.2025.05.001](https://doi.org/10.1016/bs.abl.2025.05.001).

270. Sarkar S, Carroll B, Buganim Y, Maetzel D, Ng AH, Cassady JP, Cohen MA, Chakraborty S, Wang H, Spooner E, Ploegh H, Gsponer J, Korolchuk VI, Jaenisch R. Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease. *Cell Rep.* 2013 Dec 12;5(5):1302-15. doi: 10.1016/j.celrep.2013.10.042.
271. Dall'Armi C, Devereaux KA, Di Paolo G. The role of lipids in the control of autophagy. *Curr Biol.* 2013 Jan 7;23(1):R33-45. doi: 10.1016/j.cub.2012.10.041.
272. Zhang S, Peng X, Yang S, Li X, Huang M, Wei S, Liu J, He G, Zheng H, Yang L, Li H, Fan Q. The regulation, function, and role of lipophagy, a form of selective autophagy, in metabolic disorders. *Cell Death Dis.* 2022 Feb 8;13(2):132. doi: 10.1038/s41419-022-04593-3.
273. Jarocki M, Turek K, Saczko J, Tarek M, Kulbacka J. Lipids associated with autophagy: mechanisms and therapeutic targets. *Cell Death Discov.* 2024 Oct 30;10(1):460. doi: 10.1038/s41420-024-02224-8.
274. Karim M, Mishra M, Lo CW, Saul S, Cagirici HB, Gourdelier M, Ghita L, Ojha A, Tran DHN, Agrawal A, McGraw C, East MP, Gammeltoft KA, Sahoo MK, Mooney NA, Johnson GL, Das S, Leyssen P, Neyts J, Chiu W, Cohen CA, Bukh J, Gottwein J, Dye JM, Neff N, Jackson PK, Pinsky BA, Laitinen T, Pantsar T, Poso A, Zanini F, De Jonghe S, Asquith CRM, Einav S. PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2. *Nat Commun.* 2025 Jul 10;16(1):6397. doi: 10.1038/s41467-025-61759-1.
275. Haucke V, Kozlov MM. Membrane remodeling in clathrin-mediated endocytosis. *J Cell Sci.* 2018 Sep 3;131(17):jcs216812. doi: 10.1242/jcs.216812.
276. Rigby RE, Rehwinkel J. RNA degradation in antiviral immunity and autoimmunity. *Trends Immunol.* 2015 Mar;36(3):179-88. doi: 10.1016/j.it.2015.02.001.
277. Acevedo-Whitehouse K, Bruno R. Potential health risks of mRNA-based vaccine therapy: A hypothesis. *Med Hypotheses.* 2023 Feb;171:111015. doi: 10.1016/j.mehy.2023.111015.
278. Fung SYS, Xü XJ, Wu M. Nonlinear dynamics in phosphoinositide metabolism. *Curr Opin Cell Biol.* 2024 Jun;88:102373. doi: 10.1016/j.ceb.2024.102373.
279. Thiemicke A, Neuert G. Rate thresholds in cell signaling have functional and phenotypic consequences in non-linear time-dependent environments. *Front Cell Dev Biol.* 2023 Mar 21;11:1124874. doi: 10.3389/fcell.2023.1124874.
280. Hou X, Chen Y, Carrillo ND, Cryns VL, Anderson RA, Sun J, Wang S, Chen M. Phosphoinositide signaling at the cytoskeleton in the regulation of cell dynamics. *Cell Death Dis.* 2025 Apr 14;16(1):296. doi: 10.1038/s41419-025-07616-x.
281. Adhikari H, Cullen PJ. Role of phosphatidylinositol phosphate signaling in the regulation of the filamentous-growth mitogen-activated protein kinase pathway. *Eukaryot Cell.* 2015 Apr;14(4):427-40. doi: 10.1128/EC.00013-15.
282. Wang L, Eghtesad S, Clemens PR. Migration of dendritic cells from murine skeletal muscle. *Immunobiology.* 2011 Jan-Feb;216(1-2):195-9. doi: 10.1016/j.imbio.2010.04.006.
283. Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. *Nat Rev Immunol.* 2009 Mar;9(3):153-61. doi: 10.1038/nri2496.
284. Zhang Y, Garcia-Ibanez L, Ulbricht C, Lok LSC, Pike JA, Mueller-Winkler J, Dennison TW, Ferdinand JR, Burnett CJM, Yam-Puc JC, Zhang L, Alfaro RM, Takahama Y, Ohigashi I, Brown G, Kurosaki T, Tybulewicz VLJ, Rot A, Hauser AE, Clatworthy MR, Toellner KM. Recycling of memory B cells between germinal center and lymph node subcapsular sinus supports affinity maturation to antigenic drift. *Nat Commun.* 2022 May 5;13(1):2460. doi: 10.1038/s41467-022-29978-y.
285. Chazaud B. Inflammation and skeletal muscle regeneration: Leave it to the macrophages! *Trends Immunol.* 2020 Jun;41(6):481-492. doi: 10.1016/j.it.2020.04.006.
286. Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. *Lab Invest.* 2017 Jun;97(6):669-697. doi: 10.1038/labinvest.2017.25.
287. Simonis A, Theobald SJ, Koch AE, Mummadavarapu R, Mudler JM, Pouikli A, Göbel U, Acton R, Winter S, Albus A, Holzmann D, Albert MC, Hallek M, Walczak H, Ulas T, Koch M, Tessarz P, Hänsel-Hertsch R, Rybniker J. Persistent epigenetic memory of SARS-CoV-2 mRNA vaccination in monocyte-derived macrophages. *Mol Syst Biol.* 2025 Apr;21(4):341-360. doi: 10.1038/s44320-025-00093-6.

288. Ochoa D, Bradley D, Beltrao P. Evolution, dynamics and dysregulation of kinase signalling. *Curr Opin Struct Biol.* 2018 Feb;48:133-140. doi: 10.1016/j.sbi.2017.12.008.
289. Pelley JW. Membranes and Intracellular Signal Transduction. Chapter 5 in Pelley JW, Ed. Elsevier's *Integrated Biochemistry*. Mosby, 2007, 37-46. doi: 10.1016/B978-0-323-03410-4.50011-0.
290. Grecco HE, Schmick M, Bastiaens PI. Signaling from the living plasma membrane. *Cell.* 2011 Mar 18;144(6):897-909. doi: 10.1016/j.cell.2011.01.029.
291. Mukherjee A, Huang Y, Elgeti J, Oh S, Abreu JG, Neliat AR, Schüttler J, Su DD, Dupre C, Benites NC, Liu X, Peshkin L, Barboiu M, Stocker H, Kirschner MW, Basan M. Membrane potential mediates the cellular response to mechanical pressure. *bioRxiv [Preprint]*. 2024 Nov 13:2023.11.02.565386. doi: 10.1101/2023.11.02.565386.
292. Szischik CL, Reves Szemere J, Balderrama R, Sánchez de la Vega C, Ventura AC. Transient frequency preference responses in cell signaling systems. *npj Syst Biol Appl* 2024; 10: 86. doi: 10.1038/s41540-024-00413-w.
293. Cobb MH, Goldsmith EJ. Dimerization in MAP-kinase signaling. *Trends Biochem Sci.* 2000 Jan;25(1):7-9. doi: 10.1016/s0968-0004(99)01508-x.
294. Fossett N. Signal transduction pathways, intrinsic regulators, and the control of cell fate choice. *Biochim Biophys Acta.* 2013 Feb;1830(2):2375-84. doi: 10.1016/j.bbagen.2012.06.005.
295. Landry BD, Clarke DC, Lee MJ. Studying Cellular Signal Transduction with OMIC Technologies. *J Mol Biol.* 2015 Oct 23;427(21):3416-40. doi: 10.1016/j.jmb.2015.07.021.
296. Vijay S, Gujral TS. Non-linear deep neural network for rapid and accurate prediction of phenotypic responses to kinase inhibitors. *iScience.* 2020 May 22;23(5):101129. doi: 10.1016/j.isci.2020.101129.
297. Jiang Y, AkhavanAghdam Z, Li Y, Zid BM, Hao N. A protein kinase A-regulated network encodes short- and long-lived cellular memories. *Sci Signal.* 2020 May 19;13(632):eaay3585. doi: 10.1126/scisignal.aay3585.
298. Ghomlaghi M, Hart A, Hoang N, Shin S, Nguyen LK. Feedback, Crosstalk and competition: ingredients for emergent non-linear behaviour in the PI3K/mTOR signalling network. *Int J Mol Sci.* 2021 Jun 28;22(13):6944. doi: 10.3390/ijms22136944.
299. Veres T, Kerestély M, Kovács BM, Keresztes D, Schulc K, Seitz E, Vassy Z, Veres DV, Csermely P. Cellular forgetting, desensitisation, stress and ageing in signalling networks. When do cells refuse to learn more? *Cell Mol Life Sci.* 2024 Feb 19;81(1):97. doi: 10.1007/s00018-024-05112-7.
300. Rauch N, Rukhlenko OS, Kolch W, Kholodenko BN. MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. *Curr Opin Struct Biol.* 2016 Dec;41:151-158. doi: 10.1016/j.sbi.2016.07.019.
301. Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. *Nat Rev Mol Cell Biol* 2020; 21: 6070632. doi: 10.1038/s41580-020-0255-7.
302. Parres-Gold J, Levine M, Emert B, Stuart A, Elowitz MB. Contextual computation by competitive protein dimerization networks. *Cell.* 2025 Apr 3;188(7):1984-2002.e17. doi: 10.1016/j.cell.2025.01.036.
303. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. *Nat Rev Mol Cell Biol.* 2011 Feb;12(2):104-17. doi: 10.1038/nrm3048.
304. Wen PJ, Osborne SL, Meunier FA. Phosphoinositides in neuroexocytosis and neuronal diseases. *Curr Top Microbiol Immunol.* 2012;362:87-98. doi: 10.1007/978-94-007-5025-8_4. PMID: 23086414.
305. Tsuruta F. New insights into the functions of PtdIns(3,5)P₂ in the pathogenesis of neurodegenerative disorders. *Neural Regen Res.* 2016 Feb;11(2):240-1. doi: 10.4103/1673-5374.177727.
306. Houthaeve G, De Smedt SC, Braeckmans K, De Vos WH. The cellular response to plasma membrane disruption for nanomaterial delivery. *Nano Converg.* 2022 Feb 1;9(1):6. doi: 10.1186/s40580-022-00298-7.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.